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CHAPTER 1: GENERAL INTRODUCTION 
 
Introduction 
Porcine reproductive and respiratory syndrome (PRRS) is one of the most important diseases 
of domestic swine, due to both the large economic and animal welfare impacts it causes 
worldwide.  The etiologic agent is a virus (PRRSV), which is a member of the family 
Arteriviridae.  PRRSV has proven itself to be a difficult target for control and eradication 
efforts within the swine industry since emerging in the late 1980s.  Vaccine development 
efforts have relied chiefly upon attenuated viruses due to the ineffectiveness of inactivated 
and subunit vaccines, but heterologous protection from attenuated vaccines is quite variable.  
Control efforts are further hampered by the lack of diagnostic assays that can differentiate 
vaccinated from infected animals.  Therefore, it is desirable to develop an improved 
generation of PRRS vaccines to address these and other shortcomings. 
 
Early investigations into the antigenic determinants of the PRRSV-neutralizing antibody 
response identified the major neutralizing epitope in the ectodomain of GP5 (2, 3, 5).  An 
association between N-linked glycosylation of GP5 and the antibody response to this epitope 
has also been described (1).  Work done in preparation for the series of studies presented in 
this dissertation suggested that the use of two N-glycan mutant GP5 proteins might be 
beneficial for the induction of broadly neutralizing antibody responses (D.L. Harris, 
unpublished data).  Studies presented in this dissertation, specifically in Chapters 4 and 5, 
make use of these N-glycan GP5 proteins as part of a candidate PRRS vaccine. 
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Alphavirus-derived replicon particle (RP) vaccines have been in pre-clinical development for 
well over a decade, and have demonstrated efficacy and safety in a wide range of disease and 
animal models (4).  Recently, an RP platform derived from Venezuelan equine encephalitis 
virus (strain, TC-83) has been developed for use in veterinary vaccines.  The key attributes of 
RP technology are that they are propagation-defective, single-cycle RNA virus vectors, and 
are capable of eliciting potent humoral and cellular immune responses to a wide variety of 
antigens.  The use of RP allow for native expression of viral antigens, in contrast to many 
subunit protein expression systems, which may be crucial for the development of improved 
PRRS vaccines.  The propagation-defective nature of the RP addresses one of the chief 
concerns with attenuated PRRS vaccines, which is the risk of reversion to virulence. 
 
This dissertation describes a body of work based on the application of RP technology to the 
development of control measures for PRRS.  The first manuscript of this dissertation 
describes the use of an RP influenza vaccine to reduce viral load in young pigs challenged 
with PRRSV.  This manuscript highlights the utility of RP as a platform for evaluating both 
the innate and adaptive immune responses to PRRSV infection.  The second manuscript 
describes the evaluation of two candidate RP PRRS vaccines in pregnant gilts, with a focus 
on farrowing and litter performance.  This manuscript represents one of very few attempts at 
evaluating vectored PRRS vaccines in this model.  The third manuscript presents a series of 
three experiments conducted with young pigs, wherein various candidate RP PRRS vaccines 
were evaluated in challenge studies.  The second and third manuscripts represent the only 
known systemic evaluation of multiple candidate RP PRRS vaccines. 
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Dissertation organization 
This dissertation is organized in manuscript format.  Chapter 1 includes a short introduction 
to PRRSV and RP, describes the content of the included manuscripts, and outlines the format 
of this dissertation.  Chapter 2 provides a literature review of PRRSV natural history, 
immunology, and vaccinology.  Chapters 3, 4, and 5 are manuscripts describing the research 
and results obtained by the primary research author, Mark Mogler, and co-authors.  Chapter 6 
provides general conclusions of the research, brief discussion of future work, and is followed 
by a brief acknowledgements section. 
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CHAPTER 2: LITERATURE REVIEW, PORCINE REPRODUCTIVE AND 
RESPIRATORY SYNDROME VIRUS 
	  
Introduction 
Porcine respiratory and reproductive syndrome (PRRS) is the most economically significant 
disease of swine, costing US producers over $600 million annually (47, 95).  The 
reproductive form of the disease causes fever, abortion, infertility, and low piglet viability, 
while the respiratory form causes fever, pneumonia, anorexia, and susceptibility to sequelae 
(115).  The etiologic agent of PRRS is an enveloped virus (PRRSV) containing a single-
stranded, positive-sense, RNA genome, which is a member of the Arterivirus genus in the 
order Nidovirales (10).  Due to its interesting virological and immunological properties, 
PRRSV presents a complex challenge for researchers and swine producers alike. 
 
The order Nidovirales 
The prefix ‘nido-’ is derived from the Latin ‘nidus’ for ‘nest’, and the initial organization of 
the Nidovirales order was based upon the common 5’ leader sequence on all nested 
subgenomic mRNA species.  However, this characteristic has been shown to be less 
conserved and is no longer considered a hallmark of the order (17).  The characterization of 
the multidomain replicase gene has revealed two main distinguishing genetic markers, the 
multinuclear zinc-binding domain (ZBD) and the uridylate-specific endoridonuclease 
(NendoU) (42, 43).  Other domains are generally conserved among the nidovirus replicase, 
but are shared with other virus orders. 
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The order Nidovirales can be divided into four main groups: coronaviruses, toroviruses, 
roniviruses, and arteriviruses.  Of these groups, the arteriviruses have the smallest genomes at 
approximately 15 kilobases (10).  The remaining so-called ‘large nidoviruses’ possess 
genomes of 25-32 kilobases, easily the largest known RNA genomes (41-43).  One common 
characteristic of the large nidoviruses is the presence of a 3’-to-5’ exoribonuclease (ExoN) in 
the replicase machinery, which supplies a proofreading function that likely contributes to the 
exceptional genome size of these viruses (43, 124). 
 
PRRSV biology 
The other members of the Arterivirus genus are equine arteritis virus (EAV), lactate 
dehydrogenase-elevating virus (LDV), and simian hemorrhagic fever virus (SHFV).  Of 
these, LDV is most closely related to PRRSV, and EAV is the most phylogenetically distant 
(10).  The approximately 15.5 kilobase RNA genome of PRRSV contains a 5’ leader 
sequence, ten known open reading frames (ORFs), and a 3’ untranslated, polyadenylated tail 
region.  The two most 5’-proximal ORFs (1a and 1ab) occupy approximately three-quarters 
of the genome and encode two replicase polyproteins (pp1a and pp1ab).  These two precursor 
polyproteins are extensively processed into at least twelve nonstructural proteins (nsp 1-12) 
by three viral proteases (nsp1, nsp2 and nsp4) (1, 92, 138, 156, 166).  A ribosomal frameshift 
mediates the translation of pp1ab.  The 3’ end of the viral genome contains a set of eight 
smaller genes (ORFs) that partially overlap with each other.  These genes encode the 
structural proteins of the virus and are expressed from subgenomic mRNAs (125).  The 
expression of all eight genes in the genomic 3’ end (ORFs 2a, 2b, 3, 4, 5a, 5, 6, and 7) is 
required for the production of infectious progeny virions (39, 53, 154, 155). 
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A model for PRRSV attachment, internalization, and uncoating was developed from multiple 
investigations using porcine alveolar macrophages (PAMs) and other cell types (135).  
Attachment of the virion to the host cell is mediated by heparin sulfate (26, 28, 31).  This 
interaction is relatively unstable, but the close contact allows for more stable binding of 
porcine sialoadhesin to the viral GP5/M heterodimer, and uptake of the virion is through 
clathrin-mediated endocytosis (26, 28-30, 32, 136, 141, 146).  In the early endosome, the 
scavenger receptor CD163 interacts with GP2a and GP4 to permit genome release into the 
cytoplasm (8, 19, 20, 140, 141, 151).  Acidification of the endosome and the cellular protease 
cathepsin E are also required for genome release (65).  The possibility of additional host 
factors or alternative entry pathways cannot be dismissed at this time. 
 
The replication cycle of PRRSV begins when the positive-sense RNA genome enters the host 
cell.  Translation of the replicase polyproteins from ORF1a and ORF1ab is followed by self-
processing of the polyproteins into replicase subunits (125).  The replicase complex produces 
seven nested replicative intermediate RNA strands.  These replicative intermediates are then 
used as template for transcription of the positive-sense genomic mRNA and six positive-
sense, nested, subgenomic mRNAs (33, 123, 125).  In PRRSV, as in all arteriviruses, the 
mRNAs are 3’ co-terminal and also share a 5’ leader sequence.  The addition of the 5’ leader 
sequence is accomplished by a negative-sense strand “body jump”, which in turn is regulated 
by base-pairing at the leader-body junction sites (11, 33, 83, 84, 125, 162). 
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Viral particles are assembled by nucleocapsid budding into the lumen of the smooth 
endoplasmic reticulum and/or Golgi, and viral particles are released by exocytosis (22, 125).  
Membrane proteins, including the GP5/M heterodimer, are required for viral particle 
assembly (154, 155).  Defective interfering particles have not been described for 
arteriviruses.  The viral particle is spherical and is approximately 50 nm in diameter (23, 34). 
 
History 
In the late 1980s, swine producers in the United States and Europe began reporting the 
existence of a previously unknown reproductive syndrome, variously termed: Mystery Swine 
Disease; Blue Ear Disease; Swine Infertility and Respiratory Syndrome; and Porcine 
Endemic Abortion and Respiratory Syndrome (3, 14, 86, 108, 130, 152, 153).  The causative 
agent of PRRS was isolated in the early 1990s in both Europe and North America (14, 153).  
The prototype European (Type 1) strain is Lelystad virus (LV), while the prototype North 
American (Type 2) strain is ATCC VR2332.  There is approximately 60% nucleotide 
homology between LV and VR2332, indicating their probable distinct evolutionary history 
(58, 81, 82, 129).  PRRSV is a principal component of the so-called ‘porcine respiratory 
disease complex’ (PRDC), with porcine circovirus 2, Mycoplasma hyopneumoniae, swine 
influenza virus, Pasteurella multocida, and Haemophilus parasuis (45, 59, 96, 131). 
 
The origin of the nidoviruses generally, and PRRSV specifically, remains unclear (105).  The 
nidoviruses are hypothesized to have evolved from a large RNA virus that acquired genes 
encoding antecedents of their unique replicase machinery (43).  This newfound ability to 
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support stable genome expansion allowed the nidoviruses to adapt to their respective niches 
while independently evolving their unique host interaction strategies. 
 
The arteriviruses are relatively host-restricted, in that they generally are very limited in host 
range.  Indeed, the extremely limited host cell tropism (excepting EAV) points towards a 
deep co-evolutionary relationship with the traditional host species (125).  This raises the 
question of how arteriviruses ‘jump’ between species to establish a divergent lineage.  It has 
been hypothesized that the origin of PRRSV can be traced to a common ancestor with LDV, 
and that the interaction between LDV-infected mice and swine allowed for a proto-PRRSV 
to establish itself within swine, although direct evidence for this hypothesis is limited (105). 
 
One of the hallmarks of PRRSV evolution is the wide diversity of strains.  In some instances, 
there is evidence of two distinct strains recombining to form an entirely new lineage of 
PRRSV (68).  In other cases, new lineages have been reported following the establishment of 
vaccine-like strains in geographic areas (77).  These reports highlight some of the challenges 
imposed by the mutable nature of the PRRSV genome.  Type 1 (European-like) PRRSV 
strains form three distinct subtypes (88).  The current diversity of Type 2 PRRSV strains can 
be organized into nine lineages by ORF5 nucleotide homology (121). 
 
Viral proteins 
The twelve cleavage products of pp1a and pp1ab, encoded by ORF1a and ORF 1ab, are non-
structural proteins with functions in both replication and regulation of host response (38).  
Proteolytic activity has been identified for nsp1 and nsp2 (cysteine protease), as well as nsp4 
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(serine protease) (38, 122, 125, 127, 128).  The replicase complex is formed by nsp9-12, and 
is associated with cell membranes via interactions with nsp2, nsp3, and nsp5 (126, 137, 139). 
 
The minor structural proteins account for less than 5% of the virion by mass, and include 
GP2a, GP2b (E), GP3, GP4, and ORF5a protein (22, 39, 53, 90, 157).  Alternate reading 
frames within their respective subgenomic mRNAs encode both the E and ORF5a proteins.  
The E protein has ion-channel properties, and is likely associated with viral genome release 
upon cell entry (65).  The GP2a/GP3/GP4 heterotrimer has been implicated in the interaction 
with CD163, and is a major determinant of cell tropism (19, 132).  There are reports of GP3 
existing as a secreted protein, although there appears to be strain differences in this property 
(22, 40, 79, 142).  Virus neutralizing (VN) antibodies have been associated with linear 
epitopes on GP3 (50, 147).  A VN epitope has also been identified on GP4 of Type 1 PRRSV 
(85).  In contrast to the VN epitope on GP5, which is located in a highly conserved region, 
the VN epitope on GP4 is associated with a hypervariable region and is very susceptible to 
immunoselection (16, 85, 99, 107). 
 
The nucleocapsid (N) protein, encoded by ORF7, is the most abundant viral protein by mass, 
accounting for up to 40% of viral protein (22).  The N protein exists as both a monomer and 
disulfide-linked homodimer, and is the target of monoclonal antibodies widely used as 
diagnostic reagents (78).  The main functions of the N protein are to encapsidate the viral 
genome and associate with the viral envelope proteins during budding.  The N protein may 
also function to interfere with the host immune response by blocking the activation of a type 
I interferon response via IRF3 (116). 
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The unglycosylated M (membrane) protein is encoded by ORF6, and is thought to play a key 
role in viral budding.  The M protein forms a disulfide-linked heterodimer with GP5 through 
a cysteine residue in the N-terminal ectodomain (21, 37, 80). 
 
The major glycoprotein (GP5) is encoded by ORF5, and exists as both a monomer and a 
heterodimer (GP5/M) in the virion.  The sequence of ORF5 is the basis of most phylogenetic 
analyses of PRRSV diversity (121).  The GP5/M heterodimer associates with heparin sulfate 
and sialoadhesin during cell attachment (135).  The GP5/M heterodimer also interacts with 
the GP2/GP3/GP4 heterotrimer (19).  In EAV, the ORF5 protein carries the main epitopes 
involved in virus neutralization (2).  The major neutralization epitopes of PRRSV (both Type 
1 and 2) have been mapped to the GP5 protein N-terminal ectodomain (9, 27, 99, 104, 106, 
150, 158, 163).  However, immunization of pigs with peptides corresponding to the putative 
neutralizing region does not induce VN antibodies, and further work is needed to resolve the 
issue (73).  
 
Epidemiology 
Transmission of PRRSV occurs primarily by close contact of infected and naïve pigs, as well 
as by in utero infection of fetuses (115).  The density of swine production facilities in certain 
regions raises the concern that PRRSV may be transmitted by aerosols over long distances, 
and infectious virus has been recovered from air samples up to 9.1 km from experimentally 
infected pigs (24, 100).  Field trials comparing incidence of PRRS in HEPA filter-equipped 
and unfiltered barns show significant reductions in outbreaks (25).  In these studies, some 
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filter-equipped barns experienced PRRS clinical disease, but evidence suggested possible 
introduction of PRRSV by mechanical means.  Herd closure has been shown to eliminate the 
virus from production sites, in conjunction with strict biosecurity measures (15).  Interest in 
large-scale surveillance of swine herds for pathogens, including PRRSV, has driven the 
search for alternatives to serum-based diagnostics.  The development of oral fluid-based 
diagnostics allows for relatively easy and inexpensive sample collection from swine.  Oral 
fluids have been primarily used to detect antibodies, although some studies have tested for 
viral RNA (12, 61, 74, 109, 114).   
 
Immune responses to PRRSV 
The initial innate cellular immune response to PRRSV infection is weak, and was initially 
thought to be due to suppression of the classical interferon response (89).  Recent work 
suggests that the situation is more complex, and that suppression of interferon, as measured 
by in vitro systems, may have little relevance to in vivo disease progression (87).  Genome-
wide association studies have identified a potential role for interferon-induced genes in host 
resistance to PRRSV infection (4). 
 
The initial non-neutralizing antibody response to PRRSV infection is primarily directed 
against the nucleocapsid (N) protein.  These antibodies appear in as little as five days post-
infection, and form the basis for the commercially available diagnostic ELISA (54).  Levels 
of IgG directed against PRRSV peak several weeks after infection, and slowly decline over 
the course of 6-12 months (93).  Development of neutralizing antibodies is typically delayed 
several weeks, although neutralizing titers have been reported within nine days post-infection 
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(76, 159).  Passive transfer of neutralizing antibodies into pregnant gilts provides sterilizing 
immunity, but only partial immunity is achieved in young pig passive transfer studies (75, 
98).  In early investigations, PRRSV was reported to cause antibody-dependent enhancement 
(ADE) (160, 161).  Vaccination studies conducted since those early reports have not reported 
ADE.  Passive immunization studies with serum containing high levels of neutralizing 
antibody do not support the interpretation of ADE because there is dose-dependent 
relationship between antibody and inhibition of infection (75). 
 
The cell-mediated immune response to PRRSV is thought to be responsible for ultimate 
clearance of the virus, because virus can be recovered from lungs and lymphoid tissue in the 
presence of VN antibodies (13, 64, 87, 148).  However, the correlates of an effective cell-
mediated immune response are poorly understood at this time.  Stimulation of lymphocytes 
with PRRSV antigens yields interferon-gamma production, and is thought to be important in 
ascertaining the relative strength of anti-PRRSV cell-mediated immunity (89).  More work is 
needed to resolve the questions surrounding anti-PRRSV immunity, especially the cellular 
response and the role of neutralizing antibodies (73, 87). 
 
Vaccinology 
Current approaches to PRRSV control by vaccination can be divided broadly into three 
categories: infectious viruses, inactivated viruses, and recombinant proteins.  There are 
currently three commercially available attenuated PRRSV vaccine strains licensed for sale in 
the U.S.  Attenuated vaccines have good efficacy against homologous strains, but variable 
efficacy against heterologous strains (63, 87, 89).  Inactivated vaccines have generally poor 
	   	   	   13 
efficacy, especially against heterologous strains (60).  A widespread current practice involves 
the intentional exposure of replacement breeding animals to virulent field viruses, which 
raises serious logistical and ethical concerns (87). 
 
Multiple investigators have evaluated recombinant vaccine candidates under laboratory 
conditions, with mixed results.  Viral vectors are increasingly being used as experimental 
vaccine platforms, and include both DNA and RNA vectors (18). 
 
Recent work with naked DNA vaccines shows some level of protection when expressing a 
GP3-GP5 fusion in combination with interferon alpha and gamma (35).  Three published 
studies from Chinese researchers describe the development of a pseudorabies (PRV) vector 
expressing PRRSV antigens (52, 113, 133). In these studies, expression of either GP5 or 
GP5/M induced specific antibody and cell-mediated immune responses to both PRV and 
PRRSV.  Challenged animals had reduced viremia or clinical signs compared to 
unvaccinated controls.  Recombinant adenovirus (rAd) vectors have been used to express a 
GP5-M fusion in mice, and induced neutralizing antibodies and specific lymphocyte 
responses, but was not evaluated in pigs (49).  Additional constructs expressing either a GP3-
GP5 or GMCSF-GP3-GP5 fusion were evaluated in both mice and pigs, where they induced 
specific immune responses and reduced viremia (51, 72, 149). Poxviruses, such a fowlpox 
(FPV) and modified vaccine virus Ankara (MVA), have been evaluated in a number of other 
disease models.  The use of FPV to co-express a GP3-GP5 fusion with IL-18 reduced viremia 
in a piglet challenge model (120).  Vaccination of mice with MVA expressing GP5-M 
induced neutralizing antibodies, but swine challenge studies were not reported (165). 
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RNA virus vectors have not been used extensively in PRRSV vaccinology research, although 
recently interest in this approach has increased. Transmissible gastroenteritis virus (TGEV) is 
a coronavirus, and thus distantly related evolutionarily to PRRSV.  An inactivated vaccine 
consisting of recombinant TGEV expressing PRRSV GP5 and M was used to immunize pigs.  
Vaccinated animals had improved anamnestic antibody responses after challenge, and some 
reduction in viremia was also observed (18). 
 
Immune modulators 
The use of rAd vectors to express type I interferon, in cell cultures or in vivo, shows promise 
as a means to control PRRSV infection by reducing viremia and lung pathology (6, 7, 46, 
101).  Short (20-25 bases) RNA inverted repeats (shRNA) can stimulate sequence-specific 
antiviral responses.  Investigators used rAd vectors to express PRRSV shRNA in vivo, 
thereby stimulating an RNAi effect, and reduced viremia and clinical signs were observed 
(48, 69-71).  The in vivo effect was only demonstrated at 24 hours pre-challenge, however.  
Peptide-conjugated phosphorodiamidate morpholino oligomers (PPMO) are nucleoside 
analogs with a modified backbone that resist nuclease degradation, and they also contain an 
arginine-rich peptide that promotes uptake by cells.  PPMO bind to complementary mRNA 
sequence and prevent translation by steric hindrance.  Synthetic PPMO were administered 
swine via aerosol inoculation before and after PRRSV challenge (44, 97, 102, 103, 164).  
Reduced viremia and clinical signs were observed in treated pigs compared to placebo. 
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Alphavirus replicon particles 
Alphavirus-derived replicon particles (RP) are propagation-defective RNA virus vectors, 
which have been developed as a platform for veterinary vaccines (5, 36, 143-145).  The RP 
platform has a proven record of safety and efficacy in a wide range of human and animals 
disease models (55-57, 62, 94, 110-112, 145).  Vaccination with RP induces potent cellular 
and humoral immunity, and can stimulate innate immune responses that confer protection to 
heterologous viruses (66, 67, 91, 117-119, 134).  This dissertation will present results from 
several studies that evaluated candidate RP PRRS vaccines in both pregnant gilt and young 




Since it emerged in the late 1980s, PRRS has caused significant harm to the swine industry 
worldwide.  The biology of PRRSV has hindered vaccination and control efforts, and 
improvements will require significant advances in vaccine technology.  Alphavirus-derived 
RP have proven efficacy in many disease models, allow for differentiation of vaccinated and 
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Figure 3. PRRSV replication strategy (from Snijder et al, 1998).   
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CHAPTER 3. ALPHAVIRUS REPLICON PARTICLE ADMINISTRATION PRIOR 
TO PRRSV CHALLENGE REDUCES VIREMIA 
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Abstract 
Porcine reproductive and respiratory syndrome (PRRS) causes significant economic, food 
production, and animal welfare problems for the world swine industry.  The immune factors 
responsible for prevention of PRRS virus (PRRSV) infection are poorly understood.  Further 
exploration of the factors responsible for PRRSV’s evasion of host defenses may contribute 
to improved vaccine design.  We hypothesized that vaccination of pigs with a replicon 
particle (RP) derived from Venezuelan equine encephalitis virus (strain, TC-83) would 
interfere with the natural progression of PRRSV viremia due to the robust innate immune 
responses induced by the replicon system immediately after RP injection.  To test this, we 
vaccinated young pigs with an RP vaccine against swine influenza virus and challenged with 
PRRSV at 24 or 72 hours post-vaccination.  Compared to placebo, RP-vaccinated pigs had 
reduced viremia at various time points post-challenge, as well as a reduction in total viral 
load.  The use of RP to modulate the immune system may prove useful for further study of 
PRRSV and other pathogens. 
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Introduction 
Porcine reproductive and respiratory syndrome (PRRS) is one of the most economically 
significant diseases affecting the swine industry (14, 35).  The causative agent is a virus 
(PRRSV), which belongs to the Arterivirus genus in the order Nidovirales (5, 27, 28, 32).  
PRRSV causes abortion, stillbirth, and poor piglet viability in breeding animals; in growing 
pigs, the virus causes pneumonia, anorexia, and immune suppression (40).  Currently 
available vaccines include attenuated live viruses, inactivated whole viruses, and 
recombinant protein (33).  Problems with these vaccines include a risk of reversion to 
virulence, incomplete protection, and lack of differential serological assays.  This is due in 
part to the extensive genetic and antigenic diversity of PRRSV, as well as the lack of a 
clearly identified antigenic determinant from which to design an efficacious vaccine.  
Additionally, the key determinant(s) of a protective anti-PRRSV immune response are not 
well understood.  Advancements in PRRS vaccinology will necessitate a more complete 
understanding of the immunological factors required for protection from disease (33). 
 
Early research indicated that PRRSV infection impaired the innate immune response to 
infection, leading to prolonged disease and an ineffective adaptive immune response.  For 
example, PRRSV interferes with portions of the interferon-signaling pathway, potentially 
delaying the onset of an effective antiviral state in host cells (21, 25, 26, 29).  Further work 
has revealed a more complex model for the interaction of PRRSV with the host innate 
responses.  For example, strain differences in the in vitro interferon phenotype suggest that 
PRRSV may not necessarily require the suppression of the innate immune response to cause 
disease (21, 24).  PRRSV infection does not impact the ability of pigs to mount humoral 
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responses to heterologous antigens, implying that the many relevant immune pathways are 
still functioning (31).  However, modulation of antiviral responses with recombinant 
interferon has shown promise as a means to interfere with PRRSV infection in several studies 
(3, 4, 13, 36).  Understanding of this effect may lead to the development of improved 
vaccines and control measures for PRRS. 
 
Alphavirus-derived replicon particles (RP) are propagation-defective RNA viral vectors that 
have been developed as a vaccine platform.  An alphavirus RP derived from Venezuelan 
equine encephalitis virus (VEEV) strain TC-83 shows significant promise as a vaccine 
platform for use in veterinary medicine, as has been demonstrated with swine influenza (2, 
11, 45, 47).  Extensive work in humans and other hosts has demonstrated the safety and 
efficacy of alphavirus-derived RP vaccines in a wide variety of disease models, including 
Ebola virus and botulinum neurotoxin (12, 18, 20, 38, 46).  RP vaccination results in the 
stimulation of potent humoral and cellular immune responses, in part due to the innate 
immune pathways stimulated by the intrinsic properties of alphavirus-derived RP (10, 19, 22, 
23, 34, 41-44).  The systemic antiviral state induced by an RP can even confer protection 
from heterologous viral challenge (19).  We reasoned that this inherent property of RP could 
impact the course of PRRSV infection, even in the absence of expression of PRRSV-derived 
genes from the vector.  To test this hypothesis, two animal experiments were conducted using 
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Materials and methods 
Animals 
Crossbred pigs were obtained at approximately three weeks of age from a commercial herd 
(Wilson’s Prairie View Farm, Burlington, WI) with no history of PRRSV or influenza by 
serology or clinical signs.   Pigs were randomized into groups and allowed to acclimate for 
one week.  Animals were identified using numbered ear tags and groups were comingled in a 
shared pen space. 
 
Replicon particle vaccine 
The open reading frame encoding swine influenza virus H3N2 cluster 4 hemagglutinin (H3) 
was cloned into the alphavirus replicon vector as previously described (2, 15, 45, 46).   
Replicon and helper plasmids were used as template to produce RNA transcripts in vitro.  
Purified replicon RNA and helper RNAs were mixed with Vero cells and transfected via 
electroporation (16).  Cells were incubated eighteen hours in serum-free media.  RP were 
harvested by affinity chromatography, sterile filtered, and formulated in RP diluent (PBS + 
5% sucrose + 1% normal swine serum).  The RP were tested for the presence of replication 
competent virus by serial blind passage on Vero cells, and titrated by immunofluorescence 
assay on Vero cells.  Prior to treatment of animals, RP were formulated to a titer of 5.00x108 
RP/ml (45, 47).  The placebo formulation contained only RP diluent. 
 
Virus 
The challenge strain of PRRSV (HLV349) was isolated from a clinical specimen in 2008 and 
propagated on MARC-145 cells for two passages prior to use in this study.  The challenge 
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virus inoculum was prepared by diluting stock virus in PBS to a final titer of 1.00x105 
TCID50/ml.  Titer of the PRRSV challenge inoculum was confirmed by titration on MARC-




On day -1, each group (n= 6 pigs/group) was vaccinated with 2.0 ml of either RP or placebo 
by intramuscular injection in the neck (Table 1).  The total RP dose in Group A was 1x109.  
At 24 hours post-vaccination (day 0), all animals were challenged with virulent PRRSV by 
intranasal administration of 2.0 ml virus inoculum, for a total dose of 2.00x105 TCID50.  
Blood samples were collected by jugular venipuncture on days (-7), 3, 5, 7, 10, 14, 17, and 
21.  The serum fraction was collected and stored at -80°C prior to use in diagnostic assays.  
Animals were humanely euthanized on day 21 of the study.  All animal protocols were 
reviewed and approved by the Harrisvaccines Institutional Animal Care and Use Committee 
(Protocol # 081810-01). 
 
Experiment 2 
On day -3 or day -1, each group (n= 6 pigs/group) was vaccinated with 2.0 ml of either RP or 
placebo by intramuscular injection in the neck (Table 2).  The total RP dose in Groups A and 
B was 1x109.  At 72 or 24 hours post-treatment (day 0), all animals were challenged in the 
same manner as Experiment 1.   Blood samples were collected by jugular venipuncture on 
days (-7), 1, 4, 7, 12, 14, 18, and 21.  The serum fraction was collected and stored at -80°C 
prior to use in diagnostic assays.  Animals were humanely euthanized on day 21 of the study. 
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Assays 
Viral RNA was extracted from 140 µl of serum samples using the QIAmp Viral RNA Mini 
kit (QIAGEN, Valencia, CA) according to manufacturer’s instructions, and eluted in 60 µl of 
the supplied buffer.  Extracted viral RNA was used in a quantitative real-time, reverse 
transcriptase PCR (qPCR) (Applied Biosystems, Carlsbad, CA) assay using the supplied 
RNA to construct a standard curve.  The qPCR assay was run on a C1000 thermocycler with 
a CFX96 real-time unit, and data were analyzed using CFX Manager™ software (Bio-Rad, 
Hercules, CA).  All RNA samples were run in duplicate reactions, and the mean, log-
transformed RNA copy number per 1 µl of sample RNA was used for statistical analysis.  
The qPCR results were also used to calculate the area under the curve (AUC) for each 
animal.  Briefly, the average value for each pair of consecutive time measurements was 
multiplied by the interval, and the values were summed to obtain the AUC.  In addition, 
homologous virus neutralization was assayed by fluorescent focus neutralization (FFN) using 
previously described methods (48).  PRRSV ELISA (HerdChek X3, IDEXX Laboratories, 
Westbrook, ME) was conducted according to the manufacturer’s directions.   
 
Statistical analysis 
Analysis of variance (ANOVA) was used to analyze log2-transformed FFN titers, AUC 
values, ELISA S/P ratios, and log10 transformed qPCR RNA copy number.  Analyses were 
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Results 
PRRSV ELISA 
All challenged animals became seropositive (S/P ratio ≥0.4) prior to day 21 in all 
experiments.  There were no differences between groups in the number of animals that were 
seropositive at any time point in Experiment 1 and Experiment 2. 
 
qPCR 
In Experiment 1, the RP-vaccinated group had statistically significantly lower mean qPCR 
titers for PRRSV on days 10, 14 and 17, compared to the placebo group (Figure 1).  In 
Experiment 2, the RP group vaccinated on day (-1) had significantly lower qPCR titers than 
the placebo group by ANOVA on day 14 (Figure 2). 
 
In Experiment 1, animals in the RP-vaccinated group had a significantly lower viral load, as 
determined by AUC, when compared to placebo animals.  In Experiment 2, the animals 
vaccinated on day (-3) had significantly lower viral load than placebo (p<0.05). 
 
FFN 
No statistically significant differences by ANOVA were observed in FFN titers at necropsy 
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Discussion 
These results indicate that H3 RP administered 24 hours prior to PRRSV challenge 
significantly reduces both the magnitude of viremia and total viral load in serum as measured 
by qPCR.  The observed differences in the magnitude of viremia occurred between ten and 
seventeen days post-challenge, rather than occurring in the early viremic period, as was 
hypothesized.  These data suggest that the mechanism responsible for the reduced viremia is 
not sufficiently robust to prevent the initial viremia associated with PRRSV infection.  This 
contrasts with the protective response observed in pigs that have recovered from PRRSV 
infection (including attenuated strains) prior to re-challenge (33).  The RP vaccination did not 
stimulate more rapid production of PRRSV-neutralizing antibodies following challenge, 
suggesting an alternative mechanism of viremia reduction.  Detailed immunological data, 
such as mRNA expression levels of various cytokines, were not collected in the reported 
studies, limiting conclusions about potential mechanisms.  Further examination of the role of 
various cytokines in anti-PRRSV immunity would be prudent. 
 
There are numerous examples of RP inducing a protective antiviral state in heterologous 
virus challenges.  For example, null RP (no heterologous gene) administration protected 
against homologous VEEV challenge and heterologous influenza challenge (19).  However, 
protection was not seen with heterologous vesicular stomatitis virus challenge, suggesting 
that the innate immune stimulation afforded by RP is dependent upon the nature of the virus 
challenge and relevant protective responses required for protection. 
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The studies presented here utilized RP derived from TC-83, an attenuated form of VEEV. 
The current study also used RP containing a heterologous gene, while earlier work, reported 
by Konopka et al, was conducted with RP lacking a heterologous gene (19).  Another 
potential difference arises from the fact that different strains of VEEV-derived RP have 
varying efficiencies of titration on cells in culture as determined by immunofluoresence. 
These differences have been associated with varying affinity for cellular heparan sulphate 
moieties imparted by the glycoproteins of the different strains of VEEV-derived RP (17).  RP 
derived from the V3000 VEEV glycoproteins have a low heparan sulphate affinity relative to 
RP derived from the TC-83 VEEV glycoproteins; RP derived from these VEEV strains will 
show significantly different infectious titers (and associated genome to infectious unit ratios) 
on the same cell line due to this difference (17).  It has been shown previously that animals 
dosed with TC-83 and V3000 derived RP based on equal genome equivalents induce similar 
immune responses while dosing animals with the same RP based on infectious titers induce 
significantly different immune responses.  That is, V3000 derived RP demonstrate a 100-fold 
higher genome to infectious unit ratio when compared to TC-83 RP and it appears that all of 
the V3000 derived RP genomes not measured in the in vitro titration assay are functional in 
vivo.   This characteristic could result in large differences in the amount of RP used to 
vaccinate animals and this could influence the magnitude of the innate immune response 
induced in a dose-dependent manner.  Knowledge of these differences will ensure that study 
of the induction of the innate immune system by alphavirus replicon systems can be 
compared across studies. 
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Studies conducted by the PRRS Host Genetics Consortium have identified a quantitative trait 
locus that correlates with decreased viral load after PRRSV challenge (1).  The region of the 
swine genome identified in this work contains a member of the interferon-stimulated gene 
family.  Use of adenovirus vectors expressing porcine interferon-alpha has shown that 
PRRSV viremia is delayed by administration of this vector prior to challenge (3, 4).  
Adenovirus-vectored interferon has also shown efficacy in foot and mouth disease virus 
challenge models using both swine and cattle (6-9, 30, 37).  Induction of an antiviral state, in 
this case by vectored expression of interferon, seems to be a promising approach to 
enhancing the efficacy of PRRSV vaccines.  Further studies are needed to evaluate the swine 
cytokine response to RP administration, and the use of alphavirus replicons for this purpose 
may prove useful. 
 
In the reported studies, a single administration of RP was conducted, which may have limited 
the effectiveness of this approach.  Future work should examine the relationship between 
administration strategy and various immunological and virological outcomes to further 
develop a comprehensive, mechanistic understanding of the interaction between innate 
immunity and PRRSV infection. 
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Figures	  	  
Group n= RP treatment RP dose Treatment Challenge Necropsy 
A 6 H3 1x109 RP Day -1 Day 0 Day 21 
B 6 placebo none Day -1 Day 0 Day 21 
Table 1. Experiment 1 design.  Pigs received either RP expressing hemagglutinin of H3N2 
influenza (H3) or placebo.  Vaccination was at 24 hours pre-challenge with PRRSV.   	  	  
Group n= RP Treatment RP dose Treatment Challenge Necropsy 
A 6 H3 1x109 RP Day -3 Day 0 Day 21 
B 6 H3 1x109 RP Day -1 Day 0 Day 21 
C 6 placebo none Day -1 Day 0 Day 21 
Table 2. Experiment 2 design.  Pigs received either RP expressing hemagglutinin of H3N2 
influenza (H3) or placebo.  Vaccination was at 72 hours (Group A) or 24 hours (Groups B 
and C) pre-challenge with PRRSV.   
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Figure 1. Experiment 1 quantitative real-time RT-PCR for PRRSV RNA (qPCR) results.  
The qPCR assay was conducted using RNA extracts from sera in Experiment 1.  Group A 
(n=6 pigs) was vaccinated with RP on day (-1), and group B was vaccinated with placebo on 
day (-1). No PRRSV RNA was detected in samples from day 0 post-challenge.  Group A has 
significantly lower mean RNA copies per 1 µl at 10, 14, and 17 days post-challenge 
compared to Group B when compared by ANOVA (p=0.006, p=0.005, p=0.004, 
respectively).  Data are expressed as group mean log-transformed RNA copy number per 1 µl 
of RNA extract.  Bars represent +/- one standard error of the mean.  Different letter 
superscripts between groups represent statistical significance within each timepoint.  	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Figure 2. Experiment 2 quantitative real-time RT-PCR for PRRSV RNA (qPCR).  The 
qPCR assay was conducted using RNA extracts from sera in Experiment 2.  Group A (n=6 
pigs) was vaccinated with RP on day (-3), group B (n=6 pigs) was vaccinated with RP on day 
(-1), and Group C  (n=6 pigs) was vaccinated with placebo on day (-1).   No PRRSV RNA 
was detected in samples from day 0 post-challenge.  Group B had significantly lower mean 
RNA copies per 1 µl on day 14 post-challenge, when compared to Group C when compared 
by ANOVA (p=0.032).  Data are expressed as group mean log-transformed RNA copy 
number per 1 µl of RNA extract.  Bars represent +/- one standard error of the mean.  
Different letter superscripts between groups represent statistical significance within each 
timepoint. 
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Figure 3. Viral load in experimental animals for Experiment 1 and Experiment 2.  Area 
under the curve (AUC) was calculated from qPCR output (RNA copies per 1 µl).  The AUC 
was determined by calculating the mean of two consecutive measurements (e.g. days 3 and 7 
post challenge), multiplying the result by the length of the interval (e.g. 4 days), repeating 
this process for all time points, and summing the values.  Figure 3A displays AUC data for 
Experiment 1.  Group A (n=6 pigs) was vaccinated with RP on day (-1), and group B (n=6 
pigs) was vaccinated with placebo on day (-1).  Data are the group mean AUC, and bars 
represent +/- one standard error of the mean.  Group A has a significantly lower AUC when 
compared to Group B by ANOVA (p<0.05).  Different letter superscripts between groups 
represent statistical significance within each timepoint.  Figure 3B displays AUC data for 
Experiment 2.  Group A (n=6 pigs) was vaccinated with RP on day (-3), group B (n=6 pigs) 
was vaccinated with RP on day (-1), and Group C  (n=6 pigs) was vaccinated with placebo 
on day (-1).  Data are the group mean AUC, and bars represent +/- one standard error of the 
mean.  Group A has a significantly lower AUC when compared to Group C by ANOVA 
(p<0.05).  Different letter superscripts between groups represent statistical significance 
within each timepoint. 
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CHAPTER 4: REPLICON PARTICLE PRRS VACCINE DOES NOT PROTECT 
AGAINST CHALLENGE IN A PREGNANT GILT MODEL 
 
A paper to be submitted to Vaccine 
 
Mark A. Mogler, Ryan L. Vander Veen, J. Dustin Loy, D. L. Hank Harris, Kurt I. Kamrud 
 
Abstract 
Porcine reproductive and respiratory syndrome (PRRS) is one of the most economically 
significant diseases of domestic swine worldwide.  Currently available control measures have 
had limited success in controlling PRRS within some production systems, but improved 
solutions are needed.  The use of an alphavirus-derived replicon particle (RP) vaccine 
platform has shown promise as a potential tool for the development of novel PRRS vaccine 
candidates.  First-parity gilts were vaccinated with RP-based PRRS or influenza vaccines, 
challenged with virulent PRRS virus, and observed for farrowing performance and litter 
mortality.  When compared to non-challenged controls, all challenged gilts had significantly 
worse farrowing performance and increased litter mortality.  Neither of the candidate PRRS 
vaccines provided statistically significant improvements in either farrowing performance or 
litter mortality, when compared to the influenza vaccine.  Gilts that received PRRS vaccine 
candidates developed antigen-specific antibody responses, but failed to develop detectable 
virus neutralizing antibody titers, suggesting a possible reason for vaccine failure. 
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Introduction 
Porcine reproductive and respiratory syndrome (PRRS) is responsible for significant 
economic losses in the global swine industry (5, 11).  PRRS is caused by an enveloped, 
positive-sense, ssRNA virus (PRRSV), which is a member of the Arterivirus genus in the 
order Nidovirales (1).  Other members of this genus include simian hemorrhagic fever virus, 
equine arteritis virus, and lactate dehydrogenase-elevating virus.  In pregnant swine, PRRS is 
characterized by anorexia, fever, reproductive failure (late term abortion, stillbirths, 
mummified fetuses, etc), and occasionally, death (15).  Infected neonates suffer from high 
pre-weaning mortality, sometimes reaching 100%, which may be influenced by co-infection 
with other swine pathogens (e.g. Haemophilus parasuis). 
 
Prevention of PRRS in breeding herds has been accomplished by herd closure and exclusion 
of the pathogen, but many herds suffer from recurrent outbreaks despite control measures (2). 
One control measure utilizes intentional exposure of PRRSV-naïve replacement breeding 
stock to virulent virus present on the production site.  This is intended to provide some level 
of homologous immunity to the prevalent strain(s) of PRRSV, but the practice raises serious 
ethical and logistical concerns (9).  Prevention of disease through vaccination yields 
inconsistent results, due to the variable efficacy of attenuated PRRSV against heterologous 
strains (10, 12).  Inactivated PRRSV, subunit vaccines, and vectored vaccines have shown 
relatively poor results when evaluated under experimental conditions (3, 10).  The relevant 
antigenic determinants and underlying immune correlates of protection are poorly understood 
at this time.  Most, if not all, currently available PRRS vaccines do not allow for the 
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differentiation of infected and vaccinated animals (DIVA), further hindering control efforts.  
An improved PRRS vaccine would be of great utility in future control and eradication efforts. 
 
Alphavirus-derived replicon particles (RP) are propagation-defective RNA viral vectors, and 
have been in use as a vaccine platform for over a decade (14, 16).  An alphavirus RP derived 
from Venezuelan equine encephalitis virus (VEEV) strain TC-83 has been developed, 
allowing for improved safety and simplicity in manufacturing.  The safety and efficacy of the 
TC-83-derived RP platform is well-established in various models of both human and animal 
disease, including swine influenza (17). 
 
The use of RP to express various open reading frames of PRRSV shows promise as a means 
to develop a vectored PRRS vaccine compatible with DIVA strategies.  Our group has 
developed RP that express the GP5 and M proteins of PRRSV from the same vector.  We 
have also developed a variety of RP that express individual PRRSV proteins, including GP3, 
GP4, GP5, and M.  It was hypothesized that immunization of swine with RP expressing 
various PRRSV structural components would induce protective immune responses against 
virulent, heterologous PRRSV challenge.  To test this hypothesis, an experiment was 
conducted to evaluate the effect of two candidate RP vaccines on litter performance in a 
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Materials and Methods 
Animal experiment 
First-parity gilts (n=24) were obtained from a commercial herd with no serological evidence 
or clinical history of PRRSV or swine influenza infection.  Gilts were bred by artificial 
insemination and confirmed pregnant prior to shipment.  The bred gilts all had expected 
farrowing dates within a three-day range.  Animals were randomized into four groups of six 
gilts, with three groups sharing a room, and the fourth in a separate room.  Gilts were housed 
in individual farrowing crates under BSL-2 conditions for the duration of the study. 
 
Animals arrived at the experimental facilities on approximately day 43 of gestation.  Vaccine 
administration occurred on days 50 and 71 of gestation.  On day 90 of gestation (19 days 
post-booster vaccination), the three groups sharing a space were challenged with 1x103 
TCID50 of PRRSV strain MN184c by intramuscular injection in the neck.  The fourth group 
was not challenged with PRRSV.  Blood was collected from gilts at 4, 11, and 17 days post-
challenge. 
 
Following PRRSV challenge, gilts were observed for abortions and stillbirths.  All litters 
were delivered without artificial induction of labor, and total number of piglets born alive 
was determined at 24 hours post-farrowing.  Litters were reared without cross fostering for 
two weeks post-farrowing and observed for mortality.  At termination of the study, all 
remaining animals were euthanized.  The study protocols were reviewed and approved by the 
Harrisvaccines Institutional Animal Care and Use Committee (Protocol # 050110-06). 
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Replicon particle vaccines 
Open reading frames encoding various PRRSV or swine influenza genes were cloned into the 
alphavirus replicon vector as previously described (7).  Replicon and helper RNAs were 
produced by in vitro transcription, mixed with Vero cells, and transfected via electroporation 
prior to overnight incubation (7).  Following incubation, RP were harvested by affinity 
chromatography and formulated with diluent (PBS + 5% sucrose + 1% swine serum).  Prior 
to use, RP were tested for replication competent virus by serial blind passage on Vero cells 
(17).  The titer of each RP was determined by an immunofluorescence assay on Vero cells. 
 
Each component RP to be used in the vaccine candidates was confirmed to express the 
appropriate protein product by Western blot analysis of RP-infected Vero cell lysates with 
anti-PRRSV convalescent swine serum (data not shown). 
 
Group A received a PRRS vaccine candidate containing a mixture of two RP expressing both 
GP5 and M from the same replicon RNA.  The two constructs differed in the strain of virus 
from which they derived the GP5 sequence.  Each component RP was provided at 1x109 per 
dose, or 2x109 total RP per dose. 
 
Group B received a PRRS vaccine candidate containing a mixture of five different RP, each 
expressing one of the following genes: GP3, GP4, GP5, and M.  Two of the constructs 
expressed GP5, but they differed in their parental strain.  Each component RP was provided 
at 1x109 per dose, or 5x109 total RP per dose. 
 
	   	   	   56 
Group C received a control vaccine containing RP expressing the hemagglutinin gene 
derived from a swine H3N2 influenza strain.  The titer of RP was 1x109 per dose.  Group D 
did not receive any injection, and served as a non-vaccinated, non-challenged control group. 
 
Challenge virus 
The PRRSV strain MN184c was kindly supplied by Dr. Darwin Reicks (Swine Vet Center, 
Saint Peter, MN).  This strain is heterologous to all parental strains used to develop the 
candidate RP vaccines.  The challenge material was titrated on MARC-145 cells to determine 
the infectious titer, and diluted in PBS to a final titer of 5x102 TCID50/ml prior to challenge.  
Gilts were challenged with 2.0 ml IM, for a total challenge dose of 1x103 TCID50 PRRSV. 
 
Assays 
Anti-PRRSV ELISA (HerdChek X3, IDEXX Laboratories, Westbrook, ME) was conducted 
according to the manufacturer’s instructions. Sera were tested for anti-GP5 and anti-M 
antibody responses by Western blotting.  Briefly, purified virus was run on SDS-PAGE and 
transferred to PVDF membrane.  Strips of membrane were incubated with swine serum and 
developed using anti-swine peroxidase-conjugated antibody with TMB substrate.  Bands 
corresponding to GP5 and M were identified based on molecular weight and comparison to 
positive and negative control samples.  Sera were also tested for virus neutralization by two 
methods.  The fluorescent focus neutralization assay was conducted as previously described 
(19).  Sera were tested for neutralizing antibody using porcine alveolar macrophages (PAMs) 
as previously described (18).  Homologous hemagglutination inhibition (HI) was conducted 
according to standard protocols at the University of Minnesota Veterinary Diagnostic Lab. 
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Statistical tests 
Analysis of variance (ANOVA) was used to analyze log2-transformed virus neutralization 
titers, log2-transformed HI titers, and piglet numbers at various time points.  Statistical 




No gilts seroconverted to PRRSV nucleocapsid protein prior to challenge, based on the 
HerdChek X3 ELISA.  All challenged gilts seroconverted by this assay by 17 days post-
challenge, while non-challenged gilts remained seronegative until study termination (Table 
2).  On the day of challenge, no gilts in Groups C or D had detectable anti-PRRSV GP5 and 
M antibodies by Western blot.  In Group A, all gilts had detectable anti-PRRSV GP5 and M 
antibody responses.  In Group B, five of six gilts had detectable anti-PRRSV GP5 and M 
antibodies.  Groups A and B both were vaccinated with RP that expressed GP5 and M, while 
Groups C and D were not. 
 
All gilts in Group C developed HI antibody titers to homologous H3N2 influenza virus by 
the day of challenge, with a geometric mean titer of 1:275.  No gilts in Groups A, B, or D 
developed detectable HI antibody titers at any point in the study. 
 
No gilts developed detectable (≥ 1:4) PRRSV-neutralizing antibody titers prior to challenge, 
as measured by both the PAM VN assay and the FFN assay.   
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Litter performance 
There were no statistically significant differences between groups in the average total litter 
size (both live and dead births combined).  Average live births per litter in Groups A, B, and 
C (challenged groups) were significantly lower than Group D (non-challenged group) 
(p<0.005) (Figure 1).  At one week post-farrowing, Group B had significantly lower percent 
litter survival than both Groups C and D (p<0.05) (Figure 2).  At two weeks post-farrowing, 
Groups A, B, and C had significantly lower percent litter survival than Group D (p<0.005) 
(Figure 2).  The total numbers of litters per group containing at least one piglet by two weeks 
post-farrowing were: four in Group A; two in Group B; four in Group C; and six in Group D.  
The total numbers of live piglets at two weeks post-farrowing per group were: ten in Group 
A; four in Group B; fifteen in Group C; and 53 in Group D.  
 
Discussion 
These results indicate that two PRRS vaccine candidates evaluated here did not induce a 
protective response in pregnant gilts, as measured by litter performance.  However, the 
challenge model appears to be effective at inducing significant clinical disease in all 
challenged animals.  The severity of disease induced here may have masked marginal effects 
of vaccination.  Additionally, the heterologous nature of the vaccine antigen and challenge 
virus may have contributed to the lack of protection, as has been demonstrated previously 
(8). 
 
Prior work by Osorio et al demonstrated that passive transfer of PRRSV-neutralizing 
antibodies to pregnant gilts protected offspring against PRRSV challenge (13).  The failure of 
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the RP candidate vaccines to induce neutralizing antibodies is consistent with the observed 
outcomes in litter mortality.  The antigens required to induce significant levels of PRRSV-
neutralizing antibodies remains an unresolved question.  This study used either a 
combination of GP5 and M, or a combination of GP3, GP4, GP5, and M.  It is possible that 
one or more of the antigens was not expressed in the required conformation in vivo.  It may 
also be the case that the precise manner of expression of these antigens is critical, and that 
further refinement of the RP platform is needed.  For example, it has been demonstrated that 
the three minor glycoproteins (GP2, GP3, and GP4) form a heterotrimer, and that this 
complex is required for proper protein trafficking within the host cell (4).  The RP vaccines 
in this study did not include GP2 as an antigen, and it is unlikely that RP expressing different 
proteins would co-infect the same cell in vivo.  Future work should evaluate new techniques 
to express all required components of the GP2-GP3-GP4 heterotrimer in a way that is 
conducive to proper trafficking and immune stimulation. 
 
Prior work by our group has demonstrated that the candidate vaccines evaluated here induce 
specific cell-mediated immune responses, as measured by an interferon-gamma ELISPOT 
assay (Mogler, unpublished data).  It is likely that the gilts that received the PRRS vaccine 
candidates would have mounted similar responses, but the assay was not conducted during 
this experiment.  Regardless, the induction of such a response in pregnant animals may not 
be sufficient to mediate protection from PRRSV without an accompanying neutralizing 
antibody response. 
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The lack of anti-nucleocapsid antibodies prior to challenge, as determined by ELISA, 
highlights the compatibility of the RP platform with DIVA vaccine approaches.  Given the 
inability to determine whether an individual animal is truly free of replication-competent 
PRRSV by serological tests complicates PRRS control efforts.  The use of vectored vaccines 
that are DIVA compatible would greatly improve the clarity of PRRS status descriptions for 
herds, which is currently based on evaluation of disease severity (e.g. “stable”, “unstable”, 
etc) (6). 
 
These results provide further evidence that more work is needed to determine both the 
antigen(s) necessary for stimulating an protective immune response, and the immunological 
correlate(s) of protection. 
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Figures 
 
Group # pigs Vaccine RP per dose total RP per dose 
A 6 GP5/M (n=2 strains) 1x109 ea 2x109 
B 6 GP3, GP4, M (n=1 strain each) 
GP5 (n=2 strains) 
1x109 ea 5x109 
C 6 H3-RP 1x109 1x109 
D 6 RP diluent -- -- 
Table 1. Animal experiment design.  Groups A and B received candidate PRRS vaccines, 
Group C received an RP influenza vaccine (H3-RP), and Groups A, B, and C were 
challenged with PRRSV.  Group D was not vaccinated and was not challenged with PRRSV.  
Group A received a combination of two RP, each expressing GP5 and M.  Group B received 
a combination of RP, each expressing a single gene (GP3, GP4, GP5#1, GP5#2, or M). 
 
 
Group PRRSV ELISA 
pre-challenge 






A 0/6 6/6 0/6 6/6 
B 0/6 5/6 0/6 6/6 
C 0/6 0/6 6/6 6/6 
D 0/6 0/6 0/6 0/6 
Table 2. Immunological outcomes by group presented as number positive over total animals 
per group.  Groups A and B received candidate PRRS vaccines, Group C received an RP 
influenza vaccine, and Groups A, B, and C were challenged with PRRSV.  Group D was not 
vaccinated and was not challenged with PRRSV. 
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Figure 1.  Average live piglets per litter.  The number of live births per litter was determined 
by counting live piglets at 24 hours post-farrowing.  Groups A and B received candidate 
PRRS vaccines, Group C received an RP influenza vaccine, and Groups A, B, and C were 
challenged with PRRSV.  Group D was not vaccinated and was not challenged with PRRSV.  
There were no statistically significant differences observed between groups in total litter size.  
Groups A, B, and C each had significantly lower average live births per litter when compared 
to Group D (p<0.005).  Error bars represent +/- one standard error of the mean, and groups 
were compared by ANOVA. Different letter superscripts denote statistically significant 
differences between groups. 
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Figure 2. Litter survival at one and two weeks post-farrowing.  The percentage of piglets 
remaining alive at one and two weeks post-farrowing was calculated by dividing the number 
alive at a time point by the original number born alive per litter (“1 week” and “2 weeks”).  
Groups A and B received candidate PRRS vaccines, Group C received an RP influenza 
vaccine, and Groups A, B, and C were challenged with PRRSV.  Group D was not 
vaccinated and was not challenged with PRRSV.  At one week post-farrowing, Group B 
survival was significantly lower than that of Groups C and D (p<0.05).  At two weeks post-
farrowing, Groups A, B, and C each had significantly lower survival when compared to 
Group D (p<0.005).  Error bars represent the standard error of the mean, and group 
comparisons were by ANOVA.  Different letter superscripts denote statistically significant 
differences between groups within each timepoint. 
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CHAPTER 5: REPLICON PARTICLE PRRS VACCINE REDUCES VIREMIA  
IN A YOUNG PIG MODEL 
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Mark A. Mogler, Ryan L. Vander Veen, J. Dustin Loy, D. L. Hank Harris, Kurt I. Kamrud 
 
Abstract 
Porcine reproductive and respiratory syndrome (PRRS) is one of the most economically 
significant diseases of domestic swine.  Young pigs suffer from fever, anorexia, and 
pneumonia, and have reduced productivity.  The disease is caused by an RNA virus 
(PRRSV), which is a member of the genus Arterivirus.  Vaccines have variable efficacy and 
some have a risk of reversion to virulence under field conditions, highlighting the need for 
improved vaccine technology.  Alphavirus-derived replicon particle (RP) vaccines in swine 
provide a novel approach to PRRS vaccine development.  Several RP-based candidate PRRS 
vaccines were evaluated in young pig PRRS challenge studies.  These RP vaccines expressed 
various combinations of PRRSV structural proteins, including GP3, GP4, GP5, and M.  
Vaccinated pigs developed specific humoral and cellular immune responses prior to 
challenge, although neutralizing antibodies were not detected.  Some vaccine candidates 
reduced viremia and/or viral load, as measured by quantitative RT-PCR and virus titration.  
These results demonstrate that vaccination with RP-based PRRS vaccines can reduce viremia 
in young pigs.  Therefore, it is possible that RP vaccine efficacy as a function of antigen 
expression could be further optimized to reduce both viremia and disease. 
	   	   	   67 
 
Introduction 
Porcine reproductive and respiratory syndrome (PRRS) causes large economic losses for 
swine producers through both poor reproductive performance and diminished productivity of 
finishing pigs (11, 20).  The disease is caused by an enveloped RNA virus (PRRSV), which 
belongs to the Arterivirus genus in the order Nidovirales (3).  In young pigs, PRRS is 
characterized by fever, anorexia, pneumonia, and enhanced susceptibility to co-infection by 
other swine pathogens (8, 28, 29, 31).  Piglets can be infected in utero or as neonates, but can 
also be infected through close contact as growing pigs (28). 
 
The immune response to PRRSV infection is characterized by the delayed appearance of 
virus neutralizing antibodies, although non-neutralizing antibodies can be detected as early as 
five days post-infection (17).  The initial viremia lasts for several weeks to months, but virus 
can be detected in lymphoid tissue for much longer, with occasional reappearance of viremia 
after initial clearance (1, 38).  Immunity to reinfection is generally very strong, although 
exceptions have been observed (13, 14, 30).  Immunity to a heterologous virus strain is less 
robust, although systems for determining immunologically cross-protective groups of 
PRRSV have not been systematically tested (19).  Currently available vaccines, which are 
most commonly attenuated live virus or inactivated virus, have variable efficacy (21).  This 
may be due, in part, to strain differences, host genetics, additional pathogens, and 
management practices.  The use of attenuated live PRRSV also poses the risk of reversion to 
virulence, and is not compatible with strategies to differentiate infected animals from 
vaccinated animals (DIVA). 
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Experimental efforts to determine the antigen(s) required to induce protective immunity have 
met with little success.  The structural proteins of PRRSV are the obvious targets of vaccine 
research.  Much of the work has investigated GP5 and/or M, since these two components 
comprise a large proportion of the viral particle by mass, and were initially implicated in cell 
attachment (5, 7, 33).  GP5 has been described as a target of neutralizing antibodies, and a 
neutralizing epitope in the N-terminal region of GP5 has been identified (2, 6, 23-25, 37, 40, 
41).  The minor glycoproteins (GP2, GP3, and GP4) have recently been implicated as targets 
of neutralizing antibodies as well (4, 36).  Passive transfer of neutralizing antibodies to 
pregnant gilts completely protects both the gilts and their offspring from PRRSV challenge 
(22).  However, passive transfer of the same neutralizing antibody preparation to young 
piglets gives partial protection from PRRSV challenge; in these piglets, lymphoid tissues are 
infected, but there is an absence of viremia (16). 
 
Alphavirus-derived replicon particles (RP) derived from Venezuelan equine encephalitis 
virus (VEEV) are propagation-defective RNA virus vectors (26).  The safety and efficacy of 
RP as a vaccine platform is well established in various models of human and animal disease, 
including both viral and bacterial pathogens (34).  Recently, RP derived from attenuated 
VEEV (strain, TC-83) have been developed as a veterinary vaccine platform (35).  The use 
of TC-83-derived RP allows for manufacturing under BSL-2 conditions, and adds to the 
inherent safety of the RP approach.  The successful development of TC-83-derived RP as an 
influenza vaccine in swine highlights the potential of the platform as a means to develop 
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vaccines for other swine pathogens.  To this end, RP were created that expressed various 
structural proteins of PRRSV.    
 
It was hypothesized that immunization with RP expressing PRRSV-derived genes would 
induce immune responses that afforded protection from PRRSV challenge.  To test this 
hypothesis, a series of experiments were conducted to evaluate the efficacy of several 
candidate RP vaccines in a young pig PRRSV challenge model.  The logical starting point for 
this screen was the GP5 antigen.  Our preliminary data revealed broad neutralizing antibody 
production (Mogler and Harris, unpublished data) in pigs serially infected with PRRSV 
strains HLV013 and HLV093.  GP5 from both of these strains were provided to animals in 
combination, using the RP delivery system, to mimic the protection afforded by the parental 
strains.  Furthermore, data from a previous study showed differences in immunogenicity of 
PRRSV strains (as measured by neutralizing antibody and peptide ELISA) when strains 
differ in glycosylation of GP5 (9). This glycosylation of GP5 can be successfully reproduced 
in an RP expression system (Mogler, unpublished data).  For the pig immunization trials 
presented herein, the GP5 component was either derived from a PRRSV strain with four 
predicted glycosylation sites (HLV349), or a combination of two GP5 variants lacking a 
predicted glycosylation site at either amino acid residue 34 or 44 (HLV013 and HLV093, 
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Materials and Methods 
Replicon particle vaccine 
Open reading frames encoding various PRRSV or swine influenza genes were cloned into the 
alphavirus replicon vector as previously described (12).  Replicon and helper RNAs were 
produced by in vitro transcription, mixed with Vero cells, and electroporated prior to 
overnight incubation (12).  Following incubation, RP were harvested by affinity 
chromatography and formulated with diluent (PBS + 5% sucrose + 1% swine serum).  Prior 
to use, RP were tested for replication competent virus production by serial blind passage on 
Vero cells (35).  The titer of each RP was determined by immunofluorescence assay on Vero 
cells.  Placebo formulations contained only the diluent material. 
 
Parental virus strains used in replicon vectors 
A triple-reassortant H3N2 cluster 4 swine influenza virus isolated from a clinical case in 
2008 was sequenced, and the hemagglutinin gene sequence was used to in the construction of 
a replicon vector (H3-RP) (35).  Sequences of open reading frames 3, 4,5, and/or 6 derived 
from PRRSV strains HLV013, HLV093, and HLV349 were de novo synthesized and used to 
construct replicon vectors for evaluation as vaccine candidates. 
 
Challenge virus 
The challenge strain of PRRSV (HLV349) was isolated from a clinical specimen in 2008 and 
propagated on MARC-145 cells for two passages prior to use in this study.  The challenge 
virus inoculum was prepared by diluting stock virus in phosphate buffered saline (pH 7.4) to 
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a final titer of 1x105 TCID50/ml.  Titer of the challenge inoculum was confirmed by titration 
on MARC-145 cells. 
 
Animal experiments 
All animals were obtained from a high-health status commercial herd, with no clinical or 
serological history of PRRSV or influenza infection, at approximately three weeks of age.  
All groups were challenged intranasally with 2 mL of material from the same stock of virus, 
for a total challenge dose of 2x105 TCID50 PRRSV.  At necropsy, a board-certified veterinary 
pathologist blinded to group treatments scored macroscopic lung lesions according to the 
methods described by Halbur et al (10).  The Iowa State University or Harrisvaccines 
Institutional Animal Care and Use Committees approved all animal study protocols. 
 
Experiment 1 
Pigs were randomized into groups of ten and allowed to acclimate for one week prior to the 
study’s initiation.  Pigs were vaccinated on day 0 and day 21 of the study with various 
combinations of RP vaccine candidates or placebo (Table 1).  Group A received RP 
expressing GP5 and M from HLV349; Group B received RP expressing GP5 from HLV013 
and HLV093, and M from HLV349; Group C received sham vaccine without RP.  Challenge 
occurred on day 35.  Blood samples were collected on days 35, 42, and 49.  Pigs were 
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Experiment 2 
Pigs were randomized into groups of ten or eleven and allowed to acclimate for one week 
prior to the study’s initiation.  Pigs were vaccinated on day 0 and day 21 of the study with 
various combinations of RP vaccine candidates or placebo (Table 2).  Group A received RP 
expressing GP3 and GP4 from HLV349; Group B received RP expressing GP5 from 
HLV013 and HLV093, and M from HLV349; Group C received RP expressing GP3, GP4, 
and M from HLV349 and GP5 from HLV013 and HLV093; Group D received sham vaccine 
without RP.  Challenge occurred on day 42.  Blood samples were collected on day 42, 48, 51 
and 56.  Pigs were humanely euthanized on day 56, and lung tissues were collected for 
histopathological examination.  The post-challenge period was extended to 21 days in order 
to collect additional serum samples for viremia analysis. 
 
Experiment 3 
Pigs were randomized into groups of eight and allowed to acclimate for one week prior to the 
study’s initiation.  Pigs were vaccinated on day 0 and day 27 of the study with various 
combinations of RP vaccine candidates or placebo (Table 3).  Group A received RP 
expressing GP5 from HLV349; Group B received RP expressing M from HLV349; Group C 
received RP expressing GP5 and M from HLV349; Group D received RP expressing GP3, 
GP4, and M from HLV349 and GP5 from HLV013 and HLV093; Group E received RP 
expressing GP3 from HLV349; Group F received H3-RP.  Group F served as the negative 
vaccination control, in contrast to the placebo groups in prior experiments.  The timing of the 
second vaccination was changed to day 28 in Experiment 3 to allow for the possibility of 
enhanced affinity maturation of the antibody population.  Challenge occurred on day 49.  
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Blood samples were collected on day 49, 56, 63 and 70.  Pigs were humanely euthanized on 
day 70, and lung tissues were collected for histopathological examination.  As in Experiment 
2, the post-challenge period was extended to 21 days for additional viremia analysis. 
 
Assays 
Viral RNA was extracted from serum samples using the QIAmp Viral RNA Mini kit 
(Qiagen, Valencia, CA), and processed according to manufacturer’s directions.  Extracted 
RNA samples were used in a quantitative real-time, reverse transcriptase PCR (qPCR) 
(Applied Biosystems, Carlsbad, CA) assay using the supplied RNA standards to construct a 
standard curve.  Alternatively, RNA samples were used in a similar assay (Tetracore, 
Rockville, MD) with the standard curve created with in vitro transcripts kindly provided by 
Dr. Jane Christopher-Hennings, South Dakota State University.  All qPCR samples were run 
in duplicate, and the mean, log-transformed RNA copy number per 1 µl was used for further 
analysis.  The qPCR data were used to calculate area under the curve (AUC) from day of 
challenge until study termination. 
 
Virus titration from serum samples was conducted in triplicate on MARC-145 cell 
monolayers, and the TCID50/mL of each sample was determined by measuring cytopathic 
effect for one week (27).  Sensitivity of the virus titration assay was determined to be 
>3.20x101 TCID50/ml  (data not shown).  Virus titration data were used to calculate the AUC 
from day of challenge until study termination.  Serum PRRSV neutralization titers were 
determined by fluorescent focus neutralization assay, as previously described (39).  PRRSV 
ELISA (HerdChek 2XR or HerdChek X3, IDEXX Laboratories, Westbrook, ME) was 
	   	   	   74 
conducted according to manufacturer’s directions.  Histopathological scoring of lung tissue 
was according methods described by Halbur et al (10). 
 
Statistical analysis 
Analysis of variance (ANOVA) was used to analyze AUC values, ELISA S/P ratios, log2 
transformed FFN titers, log10 transformed serum virus TCID50, and log10 transformed viral 
RNA copy number.  Microscopic and macroscopic lung lesions were compared by t-test.    
Statistical significance was set at p<0.05. 
 
Results 
Experiment 1  
Animals were vaccinated with a two-dose regimen on day 0 and day 21 of the study with 
various combinations of RP vaccine candidates or a sham vaccine, then challenged on day 
35.  Group A received RP expressing GP5 and M from HLV349; Group B received RP 
expressing GP5 from HLV013 and HLV093, and M from HLV349; Group C received sham 
vaccine without RP (Table 1). 
 
All Group A (10/10) and a majority of Group B (7/10) animals were seropositive by Western 
blot for anti-GP5 and anti-M antibodies as determined by Western blot.  No animals from 
Group C were seropositive by this assay.  Prior to challenge, no animals seroconverted to 
PRRSV nucleocapsid (N) protein as measured by IDEXX HerdChek ELISA.  All pigs 
became seropositive by study termination.  Group B mean S/P ratios were significantly lower 
than Group C at study termination (p=0.003), but no other statistically significant differences 
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were observed.  No virus neutralizing antibody titers were detected in any groups on the day 
of challenge. 
 
No significant differences were observed between groups in macroscopic or microscopic 
lung lesions, and lung pathology was mild in all pigs.  No significant differences were 
observed between groups in qPCR titers at 7 or 14 days post-challenge. Serum virus titers on 
MARC-145 cells from Groups A and B were significantly lower at 14 days post-challenge 
versus Group C (p=0.0003 and p=0.03, respectively) (Figure 1).  Virus titration AUC was 
significantly lower for Group A, when compared to Group C (p=0.0005), but no other 
differences were observed (Figure 2).  Group B ELISPOT titer was significantly higher 
versus Group C on day of challenge (p=0.01), although not significantly different post-
challenge (Figure 3). The qPCR AUC was significantly lower in Group B when compared to 




Animals were vaccinated with a two-dose regimen on day 0 and day 21 of the study with 
various combinations of RP vaccine candidates or a sham vaccine, then challenged on day 
42.  Group A received RP expressing GP3 and GP4 from HLV349; Group B received RP 
expressing GP5 from HLV013 and HLV093, and M from HLV349; Group C received RP 
expressing GP3, GP4, and M from HLV349 and GP5 from HLV013 and HLV093; Group D 
received sham vaccine without RP (Table 2). 
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No animals seroconverted to PRRSV N protein prior to challenge, and all pigs seroconverted 
by study termination.  There were no statistically significant differences between group mean 
S/P ratios at any time post-challenge.  No virus neutralizing antibody titers were detected in 
any animals pre- or post-challenge.  No statistically significant differences between groups 
were observed in either macroscopic or microscopic lung lesions, and lung lesions were mild 
in all pigs. 
 
No significant differences in qPCR titers at any time post-challenge, and no differences were 
observed in qPCR AUC.  Group C virus titration was significantly lower than Group D at 6 
days post-challenge (p=0.036); groups A, B, and C were all significantly lower than Group D 
at 9 days post-challenge (p=0.004, p=0.002, p=0.005, respectively) (Figure 5).  The area 
under the curve for virus titration was significantly lower for all vaccinated groups (A, B, and 
C) when compared to Group D (p=0.013, p=0.0006, p=0.005, respectively) (Figure 6).  
Groups B and C had significantly higher ELISPOT titers on the day of challenge than Group 
D (p=0.032 and p=0.001, respectively), but no significant differences were observed post-
challenge (Figure 7). 
 
Experiment 3 
Animals were vaccinated with a two-dose regimen on day 0 and day 27 of the study with 
various combinations of RP vaccine candidates or a sham vaccine, then challenged on day 
48.  Group A received RP expressing GP5 from HLV349; Group B received RP expressing 
M from HLV349; Group C received RP expressing GP5 and M from HLV349; Group D 
received RP expressing GP3, GP4, and M from HLV349 and GP5 from HLV013 and 
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HLV093; Group E received RP expressing GP3 from HLV349; Group F received H3-RP 
(Table 3). 
 
No animals seroconverted to PRRSV N protein prior to challenge, and all pigs seroconverted 
by study termination.  Group A had a significantly lower mean S/P ratio than Group F at 14 
and 21 days post-challenge (p=0.048 and p=0.03, respectively), but no other groups had 
group mean S/P ratios significantly different from Group F.  No virus neutralizing antibody 
titers were detected in any animals before or after challenge.  No differences in macroscopic 
lung lesions were observed, and pathology was classified as mild in all animals. 
 
There were no differences in qPCR titers or qPCR AUC in any group when compared to 
Group F.  Groups B and C had significantly lower virus titers on MARC-145 cells at 7 days 
post-challenge when compared to Group F (p=0.003 and p=0.001, respectively) (Figure 8); 
no significant differences were observed in virus titration AUC. 
 
Discussion 
These results demonstrate that reductions in PRRSV serum virus titer are achievable with a 
two-dose regimen of replicon particles expressing various combinations of GP3, GP4, GP5, 
and/or M (Figures 1, 5, and 8).  There was also an observed reduction in total viral load, as 
determined by area under the curve of viremia measures (Figures 2, 4, and 6).  The level of 
viremia in vaccinated animals was reduced by 99% compared to controls in some cases 
(Figures 1 and 5).  The mechanism(s) underlying these phenomena are unknown, although it 
appears that neutralizing antibodies are not responsible, since there was no detectable 
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PRRSV neutralizing antibody response prior to challenge in any experiments. Animals that 
received RP expressing GP5 and M developed specific antibodies by Western blot, 
suggesting a possible mechanism for the observed effect.  In two experiments, the testing of 
PBMCs with an anti-PRRSV interferon-gamma ELISPOT assay clearly demonstrated the 
induction of cellular immune responses (Figures 3 and 7). It is conceivable that both humoral 
and cellular immunity are critical to effect clinically significant protection from PRRSV 
infection.  To this end, future work to refine the antigenic composition of candidate replicon 
particle vaccines may result in potent induction of both types of immunity. 
 
Recent work has demonstrated an effect on viremia similar to that reported here, although 
that experiment used peptides corresponding to the GP5 and/or M ectodomains as 
immunogens (15).  This highlights the ability of non-neutralizing antibodies raised against 
GP5 and/or M to limit viremia, and complicates the interpretation of data from other 
challenge studies.  There is a contradiction between previous reports of neutralizing epitopes 
located on GP5 (discussed in Introduction), and recent work suggesting that the immune 
response to GP5 is not protective.  Further work is needed to resolve this discrepancy. 
 
In the studies reported here, there were four groups of pigs vaccinated with RP expressing 
only GP5 and M in combination.  Each of those groups had a statistically significant decrease 
in viremia and/or viral load.  Two additional groups received RP expressing GP5 and M in 
combination with GP3 and GP4, and one of those groups had a statistically significant 
reduction in viremia and/or viral load.  Other groups that had reductions in viremia received 
RP expressing GP3 and GP4 (one group) or RP expressing M only (one group).  No 
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significant effect on viremia was seen in groups receiving RP expressing GP3 only (one 
group) or GP5 only (one group).  These results are summarized in Table 4.  The implication 
of these results is that the strongest effect on vaccination was seen with RP expressing GP5 
and M in combination.  Further work is needed to determine the relative importance of each 
component, and the strain differences that impact vaccine efficacy. 
 
It remains possible that the neutralizing antibody response to replication-competent PRRSV 
is different in unknown, critical aspects from the response to inactivated virus, subunit 
proteins/peptides, and vectored antigens.  Novel approaches to antigen delivery, including 
advanced adjuvants and vectored vaccines, will be critical to solving this problem.  The lack 
of neutralizing antibody responses pre- and post-challenge in these studies implies that the 
candidate vaccines did not prime the animals for a more rapid and/or robust neutralizing 
antibody response.  It is possible that the vaccine candidates reported here are unable to 
induce a sufficient protective immune response in PRRSV-naïve animals.  Future work 
should examine the effects of RP vaccination in pigs previously infected with either wild-
type or attenuated PRRSV strains.  The potential differences in immune response in such an 
experiment may provide insights regarding the relevance of various subunit antigens to both 
the humoral and cellular immune responses. 
 
In each of the reported experiments, intranasal challenge with PRRSV failed to induce 
macroscopic lung lesions consistent with “severe” cases reported by other researchers and 
veterinarians (10, 18, 32, 42).  This could be due to many factors, including: the specific 
source of animals for these trials, the specific strain of PRRSV being tested, the type and 
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abundance of other pathogens at the time of challenge, and the challenge protocol itself.  The 
qPCR and virus titration data indicate that all pigs were infected and maintaining viral titers 
in serum within one week of challenge (Figures 1, 5, and 8).  Likewise, the IDEXX 
HerdChek ELISA results do not identify any obvious delay in seroconversion consistent with 
inadequate challenge.  Prior work with this challenge strain observed that challenge doses of 
2x105 TCID50, delivered intranasally in 2 mL, resulted in uniform viremia within 24-72 hours 
post-challenge (Mogler, unpublished data).  Throughout all experiments, animals that were 
vaccinated with replicon particles did not seroconvert to PRRSV N protein prior to PRRSV 
challenge, demonstrating the compatibility of the system with DIVA approaches to PRRSV 
control and eradication.  
 
Ultimately, the results presented here highlight the challenges involved in PRRSV 
vaccinology, including the variable efficacy and incomplete protection afforded by vectored 
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Figures 
 
group n= antigens RP/dose 
A 10 HLV349 GP5 
HLV349 M 
1x109 each 
B 10 HLV013 GP5 
HLV093 GP5 
HLV349 M 
5x108 ea (GP5) 
1x109 (M) 
C 10 placebo -- 
Table 1.  Group treatments for Experiment 1.  All animals received the indicated vaccination 
on day 0 and day 21 by intramuscular injection in the neck.  Antigens are described based 
upon the parental strain of PRRSV from which each gene (GP5 or M) was derived.  The 
RP/dose refers to the number of RP expressing the indicated gene contained in each vaccine 




Figure 1. Serum virus titration results for Experiment 1.  Virus titration from sera collected 
at 7 and 14 days post-challenge (dpc) was conducted on MARC-145 cells to determine 
PRRSV TCID50/mL.  Statistical comparisons were done by ANOVA.  Group A received RP 
expressing GP5 and M from HLV349; Group B received RP expressing GP5 from HLV013 
and HLV093, and M from HLV349; Group C received sham vaccine without RP.  Groups A 
and B had significantly lower viremia than Group C at 14 days post-challenge (p=0.0003 and 
p=0.03, respectively).  Error bars denote +/- one standard error of the mean.  Different letter 
superscripts denote statistically significant differences between groups. 




Figure 2.  Area under the curve for Experiment 1 serum virus titration.  Virus titration data 
were used to calculate total area under the curve (AUC), and group means were compared by 
ANOVA.  Group A received RP expressing GP5 and M from HLV349; Group B received RP 
expressing GP5 from HLV013 and HLV093, and M from HLV349; Group C received sham 
vaccine without RP.  Group A had significantly lower viral load than Group C (p=0.0005).  
Error bars denote +/- one standard error of the mean.  Different letter superscripts denote 
statistically significant differences between groups. 
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Figure 3.  Interferon-gamma production for Experiment 1.  An interferon-γ ELISPOT assay 
was conducted using PBMCs collected on the day of challenge using purified PRRSV as the 
recall antigen.  Results are displayed as group mean spot-forming units per 1x106 PBMC.  
Group A received RP expressing GP5 and M from HLV349; Group B received RP 
expressing GP5 from HLV013 and HLV093, and M from HLV349; Group C received sham 
vaccine without RP.  Group B had a significantly higher response than Group C when 
compared by ANOVA (p=0.01).  Error bars denote +/- one standard error of the mean.  
Different letter superscripts denote statistically significant differences between groups. 
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Figure 4.  Area under the curve for Experiment 1 qPCR.  The qPCR data were used to 
calculate total area under the curve (AUC), and group means were compared by ANOVA.  
Group A received RP expressing GP5 and M from HLV349; Group B received RP 
expressing GP5 from HLV013 and HLV093, and M from HLV349; Group C received sham 
vaccine without RP.  Group B had significantly lower viral load than Group C (p=0.036).  
Error bars denote +/- one standard error of the mean.  Different letter superscripts denote 
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group n= GP3 GP4 GP5 M RP/dose 
A 10 HLV349  
HLV349 
  1x108 
1x108 
























D 11     -- 
Table 2. Group treatments for Experiment 2.  All animals received the indicated vaccination 
on day 0 and day 21 by intramuscular injection in the neck.  Antigens are described based 
upon the parental strain of PRRSV from which each gene (GP3, GP4, GP5 or M) was 
derived.  The RP/dose refers to the number of RP expressing the indicated gene contained in 




Figure 5.  Serum virus titration results for Experiment 2.  Virus titration from sera collected 
at 6, 9 and 14 days post-challenge (dpc) was conducted on MARC-145 cells to determine 
PRRSV TCID50/mL.  Statistical comparisons were by ANOVA.  Group A received RP 
expressing GP3 and GP4 from HLV349; Group B received RP expressing GP5 from 
HLV013 and HLV093, and M from HLV349; Group C received RP expressing GP3, GP4, 
and M from HLV349 and GP5 from HLV013 and HLV093; Group D received sham vaccine 
without RP.  Group C had significantly lower viremia than Group D at 6 days post-challenge 
(p=0.036).  Groups A, B and C had significantly lower viremia compared to Group D at 9 
days post-challenge (p=0.004, p=0.002, p=0.005, respectively).  Error bars denote +/- one 
standard error of the mean.  Different letter superscripts denote statistically significant 
differences between groups. 




Figure 6.  Area under the curve for Experiment 2 serum virus titration.  Virus titration data 
were used to calculate total area under the curve (AUC), and group means were compared by 
ANOVA.  Group A received RP expressing GP3 and GP4 from HLV349; Group B received 
RP expressing GP5 from HLV013 and HLV093, and M from HLV349; Group C received RP 
expressing GP3, GP4, and M from HLV349 and GP5 from HLV013 and HLV093; Group D 
received sham vaccine without RP.  Groups A, B, and C had significantly lower viral load 
than Group D (p=0.013, p=0.0006, p=0.005, respectively).  Error bars denote +/- one 
standard error of the mean.  Different letter superscripts denote statistically significant 
differences between groups. 
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Figure 7. Interferon-gamma production for Experiment 2.  An interferon-γ ELISPOT assay 
was conducted using PBMCs collected on the day of challenge using purified PRRSV as the 
recall antigen.  Results are displayed as group mean spot-forming units per 1x106 PBMC.  
Group A received RP expressing GP3 and GP4 from HLV349; Group B received RP 
expressing GP5 from HLV013 and HLV093, and M from HLV349; Group C received RP 
expressing GP3, GP4, and M from HLV349 and GP5 from HLV013 and HLV093; Group D 
received sham vaccine without RP.  Groups B and C had significantly higher responses than 
Group D when compared by ANOVA (p=0.032 and p=0.001, respectively). Error bars 
denote +/- one standard error of the mean.  Different letter superscripts denote statistically 
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group n= GP3 GP4 GP5 M other dose 
A 8   HLV349   1x109 
B 8    HLV349  1x109 























E 8 HLV349     1x109 
F 8     H3 1x109 
Table 3. Group treatments for Experiment 3.  All animals received the indicated vaccination 
on day 0 and day 28 by intramuscular injection in the neck.  Antigens are described based 
upon the parental strain of PRRSV from which each gene (GP3, GP4, GP5 or M) was 
derived (except in the case of Group F).  Group F received an RP expressing the 
hemagglutinin gene of H3N2 swine influenza.  The RP/dose refers to the number of RP 
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Figure 8. Serum virus titration results for Experiment 3.  Virus titration from sera collected 
at 7, 14 and 21 days post-challenge (dpc) was conducted on MARC-145 cells to determine 
PRRSV TCID50/mL.  Statistical comparisons were by ANOVA.  Group A received RP 
expressing GP5 from HLV349; Group B received RP expressing M from HLV349; Group C 
received RP expressing GP5 and M from HLV349; Group D received RP expressing GP3, 
GP4, and M from HLV349 and GP5 from HLV013 and HLV093; Group E received RP 
expressing GP3 from HLV349; Group F received H3-RP (derived from H3N2 influenza).  
Groups B and C had significantly lower viremia at 7 days post-challenge when compared to 
Group F by ANOVA (p=0.003 and p=0.001, respectively).  Error bars denote +/- one 
standard error of the mean.  Different letter superscripts denote statistically significant 
























































































1A 10 no no no no yes (14) yes no 
1B 10 no no no yes yes (14) no yes 
1C 10 -- -- -- -- -- -- -- 
2A 10 no no no no yes (9) yes no 
2B 10 no no no no yes (9) yes yes 
2C 10 no no no no yes (6,9) yes yes 
2D 11 -- -- -- -- -- -- -- 
3A 8 no no no no no no nd 
3B 8 no no no no yes (7) no nd 
3C 8 no no no no yes (7) no nd 
3D 8 no no no no no no nd 
3E 8 no no no no no no nd 
3F 8 -- -- -- -- -- -- -- 
Table 4.  Summary table for Experiments 1, 2, and 3.  Column headings indicate the 
experiment and group ID (e.g, Experiment 1, group C = 1C), as well as various assays 
conducted in the experiment.  The terms “yes” or “no” correspond to whether the indicated 
group’s result was statistically significant when compared to the control group for that study.  
“PRRSV neut. antibody” refers to the detection of neutralizing antibodies by FFN assay; 
“lung score differences” refers to both microscopic and macroscopic lung lesions; “qPCR 
titer” refers to differences in viremia by PRRSV qPCR assay; “qPCR AUC” refers to the area 
under the curve of qPCR data; “serum virus titer (dpc)” refers to differences in serum virus 
titration, and the number in parentheses indicates the day post-challenge where differences 
were detected; “serum virus AUC” refers to area under the curve of serum virus titration 











	   	   	   91 
References 
 1.	   Allende,	  R.,	  W.	  W.	  Laegreid,	  G.	  F.	  Kutish,	  J.	  A.	  Galeota,	  R.	  W.	  Wills,	  and	  F.	  A.	  
Osorio.	  2000.	  Porcine	  reproductive	  and	  respiratory	  syndrome	  virus:	  description	  of	  persistence	  in	  individual	  pigs	  upon	  experimental	  infection.	  Journal	  of	  virology	  
74:10834-­‐10837.	  2.	   Cancel-­‐Tirado,	  S.	  M.,	  R.	  B.	  Evans,	  and	  K.	  J.	  Yoon.	  2004.	  Monoclonal	  antibody	  analysis	  of	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus	  epitopes	  associated	  with	  antibody-­‐dependent	  enhancement	  and	  neutralization	  of	  virus	  infection.	  Veterinary	  immunology	  and	  immunopathology	  102:249-­‐262.	  3.	   Cavanagh,	  D.	  1997.	  Nidovirales:	  a	  new	  order	  comprising	  Coronaviridae	  and	  Arteriviridae.	  Archives	  of	  virology	  142:629-­‐633.	  4.	   Costers,	  S.,	  D.	  J.	  Lefebvre,	  J.	  Van	  Doorsselaere,	  M.	  Vanhee,	  P.	  L.	  Delputte,	  and	  
H.	  J.	  Nauwynck.	  2010.	  GP4	  of	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus	  contains	  a	  neutralizing	  epitope	  that	  is	  susceptible	  to	  immunoselection	  in	  vitro.	  Archives	  of	  virology	  155:371-­‐378.	  5.	   Dea,	  S.,	  C.	  A.	  Gagnon,	  H.	  Mardassi,	  B.	  Pirzadeh,	  and	  D.	  Rogan.	  2000.	  Current	  knowledge	  on	  the	  structural	  proteins	  of	  porcine	  reproductive	  and	  respiratory	  syndrome	  (PRRS)	  virus:	  comparison	  of	  the	  North	  American	  and	  European	  isolates.	  Archives	  of	  virology	  145:659-­‐688.	  6.	   Delputte,	  P.	  L.,	  P.	  Meerts,	  S.	  Costers,	  and	  H.	  J.	  Nauwynck.	  2004.	  Effect	  of	  virus-­‐specific	  antibodies	  on	  attachment,	  internalization	  and	  infection	  of	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus	  in	  primary	  macrophages.	  Veterinary	  immunology	  and	  immunopathology	  102:179-­‐188.	  7.	   Delputte,	  P.	  L.,	  N.	  Vanderheijden,	  H.	  J.	  Nauwynck,	  and	  M.	  B.	  Pensaert.	  2002.	  Involvement	  of	  the	  matrix	  protein	  in	  attachment	  of	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus	  to	  a	  heparinlike	  receptor	  on	  porcine	  alveolar	  macrophages.	  Journal	  of	  virology	  76:4312-­‐4320.	  8.	   Done,	  S.	  H.,	  and	  D.	  J.	  Paton.	  1995.	  Porcine	  reproductive	  and	  respiratory	  syndrome:	  clinical	  disease,	  pathology	  and	  immunosuppression.	  The	  Veterinary	  record	  136:32-­‐35.	  9.	   Faaberg,	  K.	  S.,	  J.	  D.	  Hocker,	  M.	  M.	  Erdman,	  D.	  L.	  Harris,	  E.	  A.	  Nelson,	  M.	  
Torremorell,	  and	  P.	  G.	  Plagemann.	  2006.	  Neutralizing	  antibody	  responses	  of	  pigs	  infected	  with	  natural	  GP5	  N-­‐glycan	  mutants	  of	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus.	  Viral	  immunology	  19:294-­‐304.	  10.	   Halbur,	  P.	  G.,	  P.	  S.	  Paul,	  X.	  J.	  Meng,	  M.	  A.	  Lum,	  J.	  J.	  Andrews,	  and	  J.	  A.	  Rathje.	  1996.	  Comparative	  pathogenicity	  of	  nine	  US	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus	  (PRRSV)	  isolates	  in	  a	  five-­‐week-­‐old	  cesarean-­‐derived,	  colostrum-­‐deprived	  pig	  model.	  Journal	  of	  veterinary	  diagnostic	  investigation	  :	  official	  publication	  of	  the	  American	  Association	  of	  Veterinary	  Laboratory	  Diagnosticians,	  Inc	  8:11-­‐20.	  11.	   Holtkamp,	  D.	  J.,	  J.	  B.	  Kliebenstein,	  E.	  J.	  Neumann,	  J.	  Zimmerman,	  H.	  Rotto,	  T.	  
K.	  Yoder,	  C.	  Wang,	  P.	  Yeske,	  C.	  Mowrer,	  and	  C.	  Haley.	  2011.	  Presented	  at	  the	  International	  PRRS	  Symposium.	  
	   	   	   92 
12.	   Kamrud,	  K.	  I.,	  M.	  Custer,	  J.	  M.	  Dudek,	  G.	  Owens,	  K.	  D.	  Alterson,	  J.	  S.	  Lee,	  J.	  L.	  
Groebner,	  and	  J.	  F.	  Smith.	  2007.	  Alphavirus	  replicon	  approach	  to	  promoterless	  analysis	  of	  IRES	  elements.	  Virology	  360:376-­‐387.	  13.	   Lager,	  K.	  M.,	  W.	  L.	  Mengeling,	  and	  S.	  L.	  Brockmeier.	  1997.	  Duration	  of	  homologous	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus	  immunity	  in	  pregnant	  swine.	  Veterinary	  microbiology	  58:127-­‐133.	  14.	   Lager,	  K.	  M.,	  W.	  L.	  Mengeling,	  and	  S.	  L.	  Brockmeier.	  1997.	  Homologous	  challenge	  of	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus	  immunity	  in	  pregnant	  swine.	  Veterinary	  microbiology	  58:113-­‐125.	  15.	   Li,	  J.,	  and	  M.	  P.	  Murtaugh.	  2012.	  Dissociation	  of	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus	  neutralization	  from	  antibodies	  specific	  to	  major	  envelope	  protein	  surface	  epitopes.	  Virology.	  16.	   Lopez,	  O.	  J.,	  M.	  F.	  Oliveira,	  E.	  A.	  Garcia,	  B.	  J.	  Kwon,	  A.	  Doster,	  and	  F.	  A.	  Osorio.	  2007.	  Protection	  against	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus	  (PRRSV)	  infection	  through	  passive	  transfer	  of	  PRRSV-­‐neutralizing	  antibodies	  is	  dose	  dependent.	  Clinical	  and	  vaccine	  immunology	  :	  CVI	  14:269-­‐275.	  17.	   Lopez,	  O.	  J.,	  and	  F.	  A.	  Osorio.	  2004.	  Role	  of	  neutralizing	  antibodies	  in	  PRRSV	  protective	  immunity.	  Veterinary	  immunology	  and	  immunopathology	  102:155-­‐163.	  18.	   Metwally,	  S.,	  F.	  Mohamed,	  K.	  Faaberg,	  T.	  Burrage,	  M.	  Prarat,	  K.	  Moran,	  A.	  
Bracht,	  G.	  Mayr,	  M.	  Berninger,	  L.	  Koster,	  T.	  L.	  To,	  V.	  L.	  Nguyen,	  M.	  Reising,	  J.	  
Landgraf,	  L.	  Cox,	  J.	  Lubroth,	  and	  C.	  Carrillo.	  2010.	  Pathogenicity	  and	  molecular	  characterization	  of	  emerging	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus	  in	  Vietnam	  in	  2007.	  Transboundary	  and	  emerging	  diseases	  57:315-­‐329.	  19.	   Murtaugh,	  M.	  P.,	  and	  M.	  Genzow.	  2011.	  Immunological	  solutions	  for	  treatment	  and	  prevention	  of	  porcine	  reproductive	  and	  respiratory	  syndrome	  (PRRS).	  Vaccine	  29:8192-­‐8204.	  20.	   Neumann,	  E.	  J.,	  J.	  B.	  Kliebenstein,	  C.	  D.	  Johnson,	  J.	  W.	  Mabry,	  E.	  J.	  Bush,	  A.	  H.	  
Seitzinger,	  A.	  L.	  Green,	  and	  J.	  J.	  Zimmerman.	  2005.	  Assessment	  of	  the	  economic	  impact	  of	  porcine	  reproductive	  and	  respiratory	  syndrome	  on	  swine	  production	  in	  the	  United	  States.	  Journal	  of	  the	  American	  Veterinary	  Medical	  Association	  227:385-­‐392.	  21.	   Opriessnig,	  T.,	  P.	  G.	  Halbur,	  K.	  J.	  Yoon,	  R.	  M.	  Pogranichniy,	  K.	  M.	  Harmon,	  R.	  
Evans,	  K.	  F.	  Key,	  F.	  J.	  Pallares,	  P.	  Thomas,	  and	  X.	  J.	  Meng.	  2002.	  Comparison	  of	  molecular	  and	  biological	  characteristics	  of	  a	  modified	  live	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus	  (PRRSV)	  vaccine	  (ingelvac	  PRRS	  MLV),	  the	  parent	  strain	  of	  the	  vaccine	  (ATCC	  VR2332),	  ATCC	  VR2385,	  and	  two	  recent	  field	  isolates	  of	  PRRSV.	  Journal	  of	  virology	  76:11837-­‐11844.	  22.	   Osorio,	  F.	  A.,	  J.	  A.	  Galeota,	  E.	  Nelson,	  B.	  Brodersen,	  A.	  Doster,	  R.	  Wills,	  F.	  
Zuckermann,	  and	  W.	  W.	  Laegreid.	  2002.	  Passive	  transfer	  of	  virus-­‐specific	  antibodies	  confers	  protection	  against	  reproductive	  failure	  induced	  by	  a	  virulent	  strain	  of	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus	  and	  establishes	  sterilizing	  immunity.	  Virology	  302:9-­‐20.	  
	   	   	   93 
23.	   Ostrowski,	  M.,	  J.	  A.	  Galeota,	  A.	  M.	  Jar,	  K.	  B.	  Platt,	  F.	  A.	  Osorio,	  and	  O.	  J.	  Lopez.	  2002.	  Identification	  of	  neutralizing	  and	  nonneutralizing	  epitopes	  in	  the	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus	  GP5	  ectodomain.	  Journal	  of	  virology	  76:4241-­‐4250.	  24.	   Pirzadeh,	  B.,	  and	  S.	  Dea.	  1997.	  Monoclonal	  antibodies	  to	  the	  ORF5	  product	  of	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus	  define	  linear	  neutralizing	  determinants.	  The	  Journal	  of	  general	  virology	  78	  (	  Pt	  8):1867-­‐1873.	  25.	   Plagemann,	  P.	  G.,	  R.	  R.	  Rowland,	  and	  K.	  S.	  Faaberg.	  2002.	  The	  primary	  neutralization	  epitope	  of	  porcine	  respiratory	  and	  reproductive	  syndrome	  virus	  strain	  VR-­‐2332	  is	  located	  in	  the	  middle	  of	  the	  GP5	  ectodomain.	  Archives	  of	  virology	  147:2327-­‐2347.	  26.	   Pushko,	  P.,	  M.	  Parker,	  G.	  V.	  Ludwig,	  N.	  L.	  Davis,	  R.	  E.	  Johnston,	  and	  J.	  F.	  
Smith.	  1997.	  Replicon-­‐helper	  systems	  from	  attenuated	  Venezuelan	  equine	  encephalitis	  virus:	  expression	  of	  heterologous	  genes	  in	  vitro	  and	  immunization	  against	  heterologous	  pathogens	  in	  vivo.	  Virology	  239:389-­‐401.	  27.	   Reed,	  L.	  J.,	  and	  H.	  Muench.	  1938.	  A	  simple	  method	  of	  estimating	  fifty	  percent	  endpoints.	  The	  American	  Journal	  of	  Hygiene	  27:493-­‐497.	  28.	   Rossow,	  K.	  D.	  1998.	  Porcine	  reproductive	  and	  respiratory	  syndrome.	  Veterinary	  pathology	  35:1-­‐20.	  29.	   Rossow,	  K.	  D.,	  E.	  M.	  Bautista,	  S.	  M.	  Goyal,	  T.	  W.	  Molitor,	  M.	  P.	  Murtaugh,	  R.	  B.	  
Morrison,	  D.	  A.	  Benfield,	  and	  J.	  E.	  Collins.	  1994.	  Experimental	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus	  infection	  in	  one-­‐,	  four-­‐,	  and	  10-­‐week-­‐old	  pigs.	  Journal	  of	  veterinary	  diagnostic	  investigation	  :	  official	  publication	  of	  the	  American	  Association	  of	  Veterinary	  Laboratory	  Diagnosticians,	  Inc	  6:3-­‐12.	  30.	   Shibata,	  I.,	  M.	  Mori,	  and	  S.	  Yazawa.	  2000.	  Experimental	  reinfection	  with	  homologous	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus	  in	  SPF	  pigs.	  The	  Journal	  of	  veterinary	  medical	  science	  /	  the	  Japanese	  Society	  of	  Veterinary	  Science	  62:105-­‐108.	  31.	   Terpstra,	  C.,	  G.	  Wensvoort,	  and	  J.	  M.	  Pol.	  1991.	  Experimental	  reproduction	  of	  porcine	  epidemic	  abortion	  and	  respiratory	  syndrome	  (mystery	  swine	  disease)	  by	  infection	  with	  Lelystad	  virus:	  Koch's	  postulates	  fulfilled.	  The	  Veterinary	  quarterly	  13:131-­‐136.	  32.	   Tian,	  K.,	  X.	  Yu,	  T.	  Zhao,	  Y.	  Feng,	  Z.	  Cao,	  C.	  Wang,	  Y.	  Hu,	  X.	  Chen,	  D.	  Hu,	  X.	  Tian,	  
D.	  Liu,	  S.	  Zhang,	  X.	  Deng,	  Y.	  Ding,	  L.	  Yang,	  Y.	  Zhang,	  H.	  Xiao,	  M.	  Qiao,	  B.	  Wang,	  
L.	  Hou,	  X.	  Wang,	  X.	  Yang,	  L.	  Kang,	  M.	  Sun,	  P.	  Jin,	  S.	  Wang,	  Y.	  Kitamura,	  J.	  Yan,	  
and	  G.	  F.	  Gao.	  2007.	  Emergence	  of	  fatal	  PRRSV	  variants:	  unparalleled	  outbreaks	  of	  atypical	  PRRS	  in	  China	  and	  molecular	  dissection	  of	  the	  unique	  hallmark.	  PloS	  one	  2:e526.	  33.	   Van	  Breedam,	  W.,	  H.	  Van	  Gorp,	  J.	  Q.	  Zhang,	  P.	  R.	  Crocker,	  P.	  L.	  Delputte,	  and	  
H.	  J.	  Nauwynck.	  2010.	  The	  M/GP(5)	  glycoprotein	  complex	  of	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus	  binds	  the	  sialoadhesin	  receptor	  in	  a	  sialic	  acid-­‐dependent	  manner.	  PLoS	  pathogens	  6:e1000730.	  
	   	   	   94 
34.	   Vander	  Veen,	  R.	  L.,	  D.	  L.	  Harris,	  and	  K.	  I.	  Kamrud.	  2012.	  Alphavirus	  replicon	  vaccines.	  Animal	  health	  research	  reviews	  /	  Conference	  of	  Research	  Workers	  in	  Animal	  Diseases:1-­‐9.	  35.	   Vander	  Veen,	  R.	  L.,	  A.	  T.	  Loynachan,	  M.	  A.	  Mogler,	  B.	  J.	  Russell,	  D.	  L.	  Harris,	  
and	  K.	  I.	  Kamrud.	  2012.	  Safety,	  immunogenicity,	  and	  efficacy	  of	  an	  alphavirus	  replicon-­‐based	  swine	  influenza	  virus	  hemagglutinin	  vaccine.	  Vaccine	  30:1944-­‐1950.	  36.	   Vanhee,	  M.,	  W.	  Van	  Breedam,	  S.	  Costers,	  M.	  Geldhof,	  Y.	  Noppe,	  and	  H.	  
Nauwynck.	  2011.	  Characterization	  of	  antigenic	  regions	  in	  the	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus	  by	  the	  use	  of	  peptide-­‐specific	  serum	  antibodies.	  Vaccine	  29:4794-­‐4804.	  37.	   Weiland,	  E.,	  M.	  Wieczorek-­‐Krohmer,	  D.	  Kohl,	  K.	  K.	  Conzelmann,	  and	  F.	  
Weiland.	  1999.	  Monoclonal	  antibodies	  to	  the	  GP5	  of	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus	  are	  more	  effective	  in	  virus	  neutralization	  than	  monoclonal	  antibodies	  to	  the	  GP4.	  Veterinary	  microbiology	  66:171-­‐186.	  38.	   Wills,	  R.	  W.,	  A.	  R.	  Doster,	  J.	  A.	  Galeota,	  J.	  H.	  Sur,	  and	  F.	  A.	  Osorio.	  2003.	  Duration	  of	  infection	  and	  proportion	  of	  pigs	  persistently	  infected	  with	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus.	  Journal	  of	  clinical	  microbiology	  
41:58-­‐62.	  39.	   Wu,	  W.	  H.,	  Y.	  Fang,	  R.	  Farwell,	  M.	  Steffen-­‐Bien,	  R.	  R.	  Rowland,	  J.	  Christopher-­‐
Hennings,	  and	  E.	  A.	  Nelson.	  2001.	  A	  10-­‐kDa	  structural	  protein	  of	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus	  encoded	  by	  ORF2b.	  Virology	  
287:183-­‐191.	  40.	   Yang,	  L.,	  M.	  L.	  Frey,	  K.	  J.	  Yoon,	  J.	  J.	  Zimmerman,	  and	  K.	  B.	  Platt.	  2000.	  Categorization	  of	  North	  American	  porcine	  reproductive	  and	  respiratory	  syndrome	  viruses:	  epitopic	  profiles	  of	  the	  N,	  M,	  GP5	  and	  GP3	  proteins	  and	  susceptibility	  to	  neutralization.	  Archives	  of	  virology	  145:1599-­‐1619.	  41.	   Zhang,	  Y.,	  R.	  D.	  Sharma,	  and	  P.	  S.	  Paul.	  1998.	  Monoclonal	  antibodies	  against	  conformationally	  dependent	  epitopes	  on	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus.	  Veterinary	  microbiology	  63:125-­‐136.	  42.	   Zhou,	  Y.	  J.,	  X.	  F.	  Hao,	  Z.	  J.	  Tian,	  G.	  Z.	  Tong,	  D.	  Yoo,	  T.	  Q.	  An,	  T.	  Zhou,	  G.	  X.	  Li,	  H.	  
J.	  Qiu,	  T.	  C.	  Wei,	  and	  X.	  F.	  Yuan.	  2008.	  Highly	  virulent	  porcine	  reproductive	  and	  respiratory	  syndrome	  virus	  emerged	  in	  China.	  Transboundary	  and	  emerging	  diseases	  55:152-­‐164.	  	  
 	   	  
	   	   	   95 
CHAPTER 6: GENERAL CONCLUSIONS 
 
The results presented here demonstrate that the alphavirus replicon particle (RP) vaccine 
platform is a powerful tool for the investigation of both innate and adaptive immunity to 
PRRSV infection.  The use of RP vaccines in young pig PRRSV challenge studies provided 
significant reductions in viremia and viral load, although protection was not seen in pregnant 
gilts.  Specific humoral and cellular immune responses to PRRSV GP3, GP4, GP5, and M 
were induced by RP vaccination when used in a prime-boost vaccination strategy.  These 
studies represent the first reports of RP used for PRRS vaccinology 
 
In Chapter 3, it was shown that administration of an RP influenza vaccine (H3-RP) 24 hours 
prior to PRRSV challenge resulted in decreased viremia and decreased viral load in young 
pigs.  These data are consistent with the reported references of strong non-specific immune 
stimulation by RP, even when the vector is expressing heterologous or null genes (4, 8).  It is 
likely that innate immune factors and cytokine responses were responsible for the observed 
reductions in viremia.  Further exploration of these effects may lead to a better understanding 
of both PRRSV and RP. 
 
The H3-RP vaccinates had significantly reduced viremia between 10 and 17 days post-
challenge, suggesting that improved adaptive immunity may have been partly responsible for 
the mechanism of viral clearance.  There was no significant increase in PRRSV-neutralizing 
antibodies among animals vaccinated with H3-RP compared to controls by the end of the 
study (21 days post-challenge), which suggests that the innate immune stimulation caused by 
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RP does not result in virus-neutralizing antibody responses.  It could be that other types of 
adaptive immune responses were responsible for the effect, but those were not directly 
measured.  The work presented in Chapter 3 is the first reported use of heterologous RP 
vaccines to reduce viremia in a PRRSV challenge model.  The subsequent chapters report the 
first uses of RP to immunize both breeding animals and young pigs against PRRSV antigens. 
 
In Chapter 4, pregnant gilts were immunized with two candidate RP PRRS vaccines and 
challenged with virulent virus.  The RP PRRS vaccines expressed either the GP5/M 
heterodimer, or a combination of GP3, GP4, GP5, and M.  As a control, one group of gilts 
received the same H3-RP vaccine that was described in Chapter 3.  Neither of the RP PRRS 
vaccine groups had significantly improved litter outcomes compared to the control group.  
Furthermore, the three PRRSV-challenged groups all had significantly increased litter 
mortality when compared to non-challenged controls.  No vaccinated animals developed 
virus-neutralizing antibodies prior to challenge, but all animals were successfully challenged 
with PRRSV based on seroconversion to N protein. 
 
Despite the lack of efficacy, the RP proved to be safe when administered to pregnant swine, 
which is encouraging for future developmental efforts.  The RP vaccine is also compatible 
with strategies for differentiating infected from vaccinated animals (DIVA), which is a major 
advantage of RP (and other subunit or vectored) vaccines for future PRRSV control and 
elimination efforts. 
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Chapter 5 presents the results of three candidate RP PRRS vaccine evaluation studies in 
young pigs.  In these studies, the RP PRRS vaccines expressed combinations of GP3, GP4, 
GP5, or M.  Reductions in viremia and/or viral load were observed in each study, suggesting 
that the RP vaccines provided partial protection from challenge. 
 
None of the vaccinated animals in the Chapter 5 studies developed PRRSV-neutralizing 
antibodies prior to challenge, as in the pregnant gilt study.  However, vaccinated animals 
developed significant PRRSV-specific cellular immune responses, based on an interferon-	  γ 
ELISPOT assay.  No vaccinated animals seroconverted to N protein prior to challenge, again 
demonstrating the compatibility of RP with DIVA strategies.  Clinical disease in all trials 
was mild, and no significant differences were observed in lung pathology.  The lack of 
significant lung pathology in the young pig challenge trials is interesting, given the published 
record of significant clinical disease in similar challenge models (3).  However, the viremia 
observed in serum samples collected in all young pig studies was remarkably consistent 
across studies.  Perhaps the source of experimental animals used for these studies played a 
role, as there were never noticeable lesions associated with bacterial co-infection at necropsy.  
Reduction of PRRSV viral load has been associated with improved weight gain in genomic 
mapping studies, although causality has not been proven at this time (1). 
 
The failure of the candidate PRRS vaccines to elicit a neutralizing antibody response in either 
pregnant gilts or young pigs was unexpected.  Neutralizing epitopes have been described in 
the ectodomain regions of GP5, GP4, and GP3, and each of these antigens were expressed by 
RP in the described studies (2, 6, 7, 9-12).  Expression analysis was performed for each RP 
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tested in the described studies by infecting Vero cells with RP, harvesting cell lysates, and 
conducting Western blot with various reagents.  Results of those Western blots were 
consistent with the interpretation that the RP candidates were capable of expressing the 
desired protein.  Immunogenicity of the GP5 and M components was confirmed by 
seroconversion of vaccinates to viral GP5 and M, as measured by Western blot.  
Unfortunately, technical difficulties with the assay prevent analysis of the GP3 and G4 
components. 
 
It appears likely that the non-neutralizing antibody generated against GP5 and/or M was able, 
in part, to reduce viremia in young pigs, at least in some instances.  This observation is 
consistent with recent reports that demonstrate viremia reduction due to non-neutralizing 
anti-GP5 antibodies (5).  Data collected by our group, but not presented here, are also 
consistent with this interpretation.  Published reports by other investigators demonstrate a 
similar magnitude of viremia reduction, although there are occasional reports of concurrent 
neutralizing antibody responses in those studies.  Regardless, the overall theme of PRRS 
vaccine development efforts with inactivated, subunit, and vectored vaccines is that of 
reduced viremia and/or clinical signs, without the near-sterilizing protection afforded by 
attenuated, homologous vaccine.  This points to a profound difference in the nature of the 
immune response to native PRRSV infection versus inactivated or vectored vaccines. 
 
The body of work presented here raises the question of whether it is possible to elicit 
meaningful neutralizing antibody titers by immunization with vectored vaccines.  It appears 
that further work will be needed to determine the appropriate antigenic requirements for 
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inducing such a response.  One strategy for elucidating the relevant antigens may involve 
combining proteomics-based approaches to antigen discovery, rather than simply using 
inference from already defined, whole viral proteins.  Another strategy may require the 
expression of non-native antigens in order to expose the relevant epitopes to the immune 
system in a manner compatible with vector-based delivery.  Whatever the strategy used to 
determine these protective antigens, the work presented here make a strong case that RP 
would be useful as a delivery mechanism.  
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